Stock abbreviation: BGI Genomics

Stock code: 300676

2025 Environmental Social and Governance Report01 Good Governance for a Solid Foundation and 03 Green Innovation for Appendix I: Key Performance Indicator 117

Steady Progress Shared Ecological Benefit

Appendix II: Report Index 121

Corporate Governance 21 Environmental Compliance Management

83 Appendix III: Reader Feedback Form 123

Risk and Compliance Management 27

Pollutant and Waste Management 87

Business Ethics 31

Addressing Climate Change 90

Energy Management and Circular

Economy 92

Ecosystem and Biodiversity Conservation

94

02 Quality First People-Oriented: Intelligence for Life 04 Inclusiveness for the Common Good

Product Safety and Quality 39 Employee Employment 97

Customer Service 49 Protection of Employee Rights 99

Innovation-Driven Development 59 Employee Training and Development 102

About This Report 01

Data Security and Customer Privacy 67 Occupational Health and Safety 107

About BGI Genomics 05 Supply Chain Management 73 Healthcare Accessibility and Inclusive

Healthcare 110

Sector Collaboration 78

ESG Management 09

Special Topic

Intelligently Shaping the Future

of GenomicsEmpowering a New

Ecosystem of Precision Medicine

with Digital Intelligence 15

CONTENTSBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

About This Report

Introduction

This Report is the Environmental Social and Governance Report issued by BGI Genomics Co. Ltd. (hereinafter

referred to as "BGI Genomics" or the "Company") to its stakeholders. The Company has systematically reviewed

and presented its key ESG management initiatives progress and performance in 2025 framed within the three

dimensions of environment society and corporate governance. This Report illustrates the Company's approaches

and achievements in implementing sustainability concepts in its daily operations and management activities.Through clearer and more traceable disclosure of responsibility information the Company hopes to help all

stakeholders fully understand its ESG practices and respond promptly to their concerns and expectations.Reporting Period Global Reporting Initiative (GRI) Standards

This Report covers the period from January 1 2025 to December 31 2025. To enhance comparability some content Self-Regulatory Guidelines No. 2 for Listed Companies on Shenzhen Stock Exchange – Standardized Operation of

has been appropriately extended to previous and subsequent years. Companies Listed on the ChiNext Market

Reporting Boundary Self-Regulatory Guidelines No. 17 for Listed Companies on Shenzhen Stock Exchange – Sustainability Report (for Trial

This Report is based on BGI Genomics Co. Ltd. as the main entity. Unless otherwise specified the scope of this Implementation)

Report is consistent with the scope of the Company's consolidated financial statements for its 2025 annual report Self-Regulatory Guidance No. 3 for Companies Listed on the ChiNext Market of Shenzhen Stock Exchange –

covering the group's headquarters and its subordinate branches and subsidiaries. Preparation of Sustainability Reports

Data Sources Definitions

The qualitative and quantitative information used in this Report is derived from BGI Genomics' official internal For ease of expression and reading BGI Genomics Co. Ltd. is also referred to as "BGI Genomics" the "Company" or

documents and annual reports. The data disclosed in this Report is sourced from the Company's actual operational "we" in this Report.raw data publicly available government data annual financial data internal statistical reports third-party surveys How to Obtain the Report

and third-party evaluation interviews. The financial data in this Report is denominated in RMB. In case of any

This Report is available in electronic format. You can view it on the Company's website (https://www.bgi.com/) or on

discrepancies with the Company's annual financial report the annual financial report shall prevail.CNINFO (http://www.cninfo.com.cn). If you have any questions or suggestions regarding this Report please send an

Preparation Basis email to info@genomics.cn or call +86-755-36307265

United Nations Sustainable Development Goals (SDGs)

1 2BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

2026: A New Journey of Integrity and Innovation

— Safeguarding Public Health Through Genomics

quality development.With stable growth as our foundation we are committed to improving quality and efficiency and serving public

well-being. We will continue to focus on the steady growth and profitability of our core business strengthen lean

operations and cost control and build a solid foundation for development through sound management. We will

steadfastly uphold our mission of "Omics for All" making dedicated progress in critical public-need areas such as

reproductive health cancer prevention and control infectious diseases and chronic disease management. We will

use cutting-edge technology to build a strong line of defense for public health and safeguard the well-being of every

family with the warmth of technology.With intelligent large models at our core we will transition to a life and health intelligence platform. We will

To all our partners friends from all walks of life comprehensively promote the deep integration of AI and life sciences. Using the large-scale application of the GeneT

who care for and support BGI Genomics and clinical large model as a key entry point we will significantly improve the efficiency of pathogenic site analysis

every investor:

Chairman reduce the cost of gene interpretation and strive to close the loop between data governance and clinical translation.This will drive the Company's transformation from a gene testing service provider to a life and health intelligence

Wang Jian platform. By training vertical-domain life science large models with multi-omics data we aim to bring gene testing

into the hundred-yuan era. Meanwhile our SIRO high-throughput gene testing localized medical solution integrates

the four core advantages of standardization automation informatization and intelligence truly realizing the large-

scale and in-depth application of artificial intelligence technology in the field of gene sequencing.The year 2025 was a year of transformation building momentum and steady quality improvement for BGI Genomics.We remained true to our original aspiration in scientific research deepened our industrial application and With globalization as our wings we will expand into the "Belt and Road" and BRICS countries. We will make overseas

continuously solidified our foundation in technological innovation and global expansion leveraging our proprietary expansion a core engine for growth adhering to a country-specific and deeply localized approach. Through

technology platforms and core big data advantages to gather momentum for a new round of strategic upgrades. This a "technology export + local cooperation" model we will deepen overseas technology transfer and industrial

confidence in our steady progress is inseparable from the valuable experience accumulated through the dedicated implementation integrate local supply chains and collaborate with other Chinese enterprises going abroad to bring

efforts of our past management teams and even more so from the united and concerted efforts of all BGI employees China's gene technology standards and services to the world.and partners from all sectors.In 2026 challenges and opportunities coexist and our original aspiration and mission go hand in hand. Standing at

The year 2026 is a crucial year for forging ahead and achieving breakthroughs. As the inaugural year of the "15th the forefront of an era where biotechnology and the digital economy are deeply integrated all of us at BGI will always

Five-Year Plan" we are closely following the national strategic direction driven by technological innovation and embody the rigor of researchers the passion of entrepreneurs and the responsibility of strivers. We will empower life

meeting the era's demand for technological self-reliance seizing the momentum to plan for the long term. The Year sciences with AI connect the world through globalization and work together to create a magnificent vision of gene

of the Horse symbolizes momentum and breakthroughs. Standing at the forefront of an era where bio-intelligence technology safeguarding life and benefiting all of humanity!

and globalization are deeply integrated BGI Genomics will be driven by the twin engines of AI and globalization. We

will anchor our efforts in three major directions: "stable growth in core business leapfrog development of our life

platform and incremental expansion of our global footprint" as we forge ahead to embark on a new journey of high-

3 4BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

About BGI Genomics In the field of reproductive health the Company provides a complete "Five-pre" maternal and child health management product system covering the pre-marital pre-conception prenatal neonatal and child growth

stages. In cancer prevention and control it has formed a closed-loop management system for the entire life cycle of

Company profile tumors focusing on "prevention screening diagnosis and monitoring" offering comprehensive testing services at

each stage. For chronic disease management the Company is committed to improving the efficiency of screening

As a leader in the global genomics sector BGI Genomics upholds the mission of "Omics for All." Through over 20 and treatment for cardiovascular and cerebrovascular diseases and cognitive disorders promoting a diagnosis and

years of talent acquisition scientific research and industrial development we have established a marketing and treatment model centered on prevention and proactive health. In the area of infection prevention and control it has

service network covering more than 100 countries and all provinces municipalities and autonomous regions in developed precise testing product solutions for everything from common community infections to complex hospital-

China. We have become one of the few technology companies that cover the entire industry chain and all application acquired infections meeting the needs of all-scenario testing.fields in our sector. Leveraging our technologically advanced fully equipped and large-scale multi-omics output

platform we have become one of the world's few providers of scientific and technological services and operators of Business regions

precision medicine services.Main business Headquartered in Shenzhen China the Company has branches and medical laboratories in major domestic cities

The Company's main business is to provide research services comprehensive solutions for precision medicine such as Beijing Tianjin Wuhan Shanghai and Guangzhou. It also has overseas centers and core laboratories in

testing and health management services for scientific research institutions enterprises and public institutions regions including Hong Kong Europe Asia-Pacific and the Middle East. It has established a network that covers

medical institutions and social health organizations through multi-omics and big data technologies such as gene the entire country and reaches globally with business operations in over 100 countries and regions. This includes

testing mass spectrometry testing bioinformatics analysis and medical intelligent large models. more than 2000 research institutions and 2400 medical institutions in China over 3000 overseas medical and

research institutions in Europe the Americas and the Asia-Pacific region and cooperative relationships with health

authorities in more than 30 countries and regions.Corporate culture

Premarital and pre-pregnancy Prenatal Newborn Children & Adolescents

Infertility Mission Vision

Miscarriage cause

investigation

Chromosomal

Pregnancy "Omics for All" Health and Beauty Leading the Life abnormality

testing (CNV-seq) Science Era

Childbirth

Secondary prevention Tertiary prevention Auxiliary diagnosis

Non-invasive prenatal testing Newborn hearing loss Genetic disease testing

Primary prevention (NIFTY) gene screening (CNV-seq WGS)

Infertility IVF Non-invasive prenatal testing Newborn screening for

Expanded carrier for multiple monogenic inherited metabolic

screening for diseases diseases Precision medication

thalassemia genes Selection of Prenatal diagnosis of genetic Newborn genetic Genetic testing

healthy embryos diseases (CNV-seq WGS) disease screening for personalized

Preimplantation Prenatal nutrition testing medication guidance

genetic testing (PGT) for children

Middle-aged and elderly

Infection Cancer Chronic diseases

Precision diagnostics Cancer prevention Early cancer screening Risk assessment Nutritional

High-throughput genetic Genetic testing for DNA methylation testing Genetic testing for metabolism

testing for pathogenic hereditary tumors for colorectal cancer hereditary cardiovascular Precision

microorganisms HPV genotyping test DNA methylation testing diseases nutrition testing

Targeted genetic testing for Helicobacter pylori for liver cancer Genetic testing for the risk Precision Core Values

pathogenic microorganisms testing DNA methylation testing of premature coronary metabolism

Multiplex nucleic acid for cervical cancer heart disease testing

testing for pathogenic Companion Recurrence monitoring Homocysteine metabolism Unlocking the Mysteries of Life Composing a New microorganisms diagnostics pathway testing

Influenza A/B virus antigen Customized MRD testing Genetic testing Trimethylamine N-oxide self-test for tumors (TMAO) metabolism Industrial Chapter and Experiencing a Wonderful Lifefor personalized pathway testing

Medication guidance diagnosis and

treatment of single Multiple neurocarboxylic

Multiplex testing for bacterial cancer types acid testing

drug resistance genes Genetic testing Genetic testing for cognitive

Mycobacterium tuberculosis for personalized disorders

and drug resistance gene diagnosis and

testing treatment of pan- Precision medication

solid tumors Genetic testing for personalized medication

guidance for adults

Therapeutic drug monitoring

56

Marriage and pregnancyBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Core honors of 2025

2025 Top 20 Chinese Biopharmaceutical Companies for

ESG Performance

2025 Top 500 Chinese Enterprises for ESG

Competitiveness Selected as a demonstrative case in "Biomedicine" for ChinaFund "2025 China Listed Companies Yinghua Won two first prizes of the 2024 Guangdong Provincial

new quality productive forces practice by the Global Award – A-share ESG Demonstration Case" Science and Technology Progress Award

Times

Selected for the "Top 100 Listed Healthcare Companies Selected as one of 36Kr's "2025 Innovative Enterprises Recognized as "Outstanding Sci-tech Innovation "Large-scale Application of AI-driven Precision Medicine

by Innovation Capability" for Globalization" Enterprise of the Year" Big Data" won the People's Artisan Technology Award

Selected by the National Data Administration as

Selected into the 2025 China Technology Fast 50 a pioneering unit for "High-quality Sector Dataset

Construction"

7 8BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

ESG management

Communications with stakeholders

BGI Genomics identifies government and regulatory agencies shareholders and investors customers employees

suppliers and partners and the community and public as its core stakeholders. Through regular communication

mechanisms such as earnings calls investor surveys customer forums employee interviews and supplier

conferences the Company continuously collects stakeholder requests and suggestions to align its ESG work with

their needs and concerns.BGI Genomics' key stakeholders and communication methods

Stakeholders Topics of concern Communication and response channels Stakeholders Topics of concern Communication and response channels

Corporate governance Corporate governance

Risk and compliance management Convening of the Two Meetings Risk and compliance management Regular communication and reporting

Anti-commercial bribery and anti- Periodic information disclosure Anti-commercial bribery and anti- On-site review

corruption Internal audit corruption Institutional research

Shareholders and senior Anti-unfair competition Roadshows and communication with the Government and Ethics of science and technology Policy implementation

management Due diligence Company regulatory agencies Environmental compliance management Information disclosure

Communications with stakeholders Pollutant and waste management

Supply chain security

Product safety and quality On-site communication Public bidding meetings

Industry collaboration

Customer service Market research Supplier audit

Product safety and quality

Innovation-driven development Customer complaint handling Strategic cooperation

Customer service

Data security and customer privacy Customer satisfaction surveys Participation in industry exhibitions

Customers Partners Equal treatment to small and medium-

protection Information security protection Exchange visits

sized enterprises

Employee activities

Employee employment Employee training Pollutant and waste management Environmental management

Protection of employee rights Employee care Contributions to the society and rural Community volunteer activities

Employee training and development Employee forums revitalization Medical community activities

Community public and

Employees Occupational health and safety Employee handbook Medical accessibility Social welfare support projects

media

Employee health check-ups

9 10BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Double materiality analysis Environmental dimension Social dimension Governance dimension

In 2025 guided by national policies research on domestic and international social responsibility standards 1.Environmental compliance management 8.Contributions to the society and 15.Protection of employee rural revitalization rights 22.Corporate governance

and industry benchmarking BGI Genomics conducted a systematic materiality analysis based on its business

development strategy operational management practices and key stakeholder concerns. Through a process of topic 2.Energy usage 9.Innovation-driven development 16.Employee training and 23.Risk and compliance development management

identification assessment and confirmation the Company ultimately identified a total of 27 material ESG topics to

address stakeholder demands more effectively. The Company prioritized these topics based on the two dimensions 3.Water resource management 10.Supply chain security 17.Occupational health and 24.Anti-commercial bribery and safety anti-corruption

of financial materiality and impact materiality providing a basis for defining annual sustainability management

priorities optimizing implementation sequences and setting long-term and specific ESG goals. 18.Equal treatment to

4.Pollutant and waste management 11.Product safety and quality small and medium-sized 25.Anti-unfair competition

enterprises

BGI Genomics' materiality analysis steps

5.Circular economy 12.Customer service 19.Ethics of science and technology 26.Due diligence

6.Ecosystem and biodiversity conservation 13.Data security and customer privacy protection 20.Medical accessibility

27.Communications with

Step 1 Topic benchmarking and screening stakeholders

7.Addressing climate change 14.Employee employment 21.Industry collaboration

Based on the Company's business development and current ESG management status and with reference

to the latest national sustainability policies and mainstream domestic and international sustainability

standards the Company comprehensively identifies ESG topics related to its business operations and

sustainability management. This process also involves benchmarking against the information disclosure 10

practices of leading peers and the key focus areas of mainstream ESG rating agencies in the capital 12 11

9

market. 9 19 13

72023

4

882417

2116

2115

Step 2 Communications with stakeholders 7 10

52214

663

The Company continuously monitors social needs and policy trends including regulatory requirements

sustainability status and trends and capital market dynamics. Through diverse communication 5 27

channels it maintains communication and exchanges with stakeholders establishing and preserving 254 26

essential positive relationships to fully understand their key concerns and feedback on sustainability 18

matters. 3

2

Step 3 Topic materiality assessment

12345678910

Building on prior identification and communication the Company further conducted a materiality Financial materiality

analysis to screen and confirm key topics closely related to sustainability. Integrating stakeholder

concerns the Company systematically assessed the relevance of each topic to its development and its With financial materiality but not impact

impact on stakeholders and prioritized them accordingly ultimately identifying three double materiality With both financial and impact materiality materiality

topics.With impact materiality but not financial Without financial or impact materiality

materiality

1112

Impact materialityBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Sustainability governance

In accordance with the Working Rules of the Board of Directors' Environmental Social and Governance (ESG) Committee

BGI Genomics has established and continuously improved its sustainability governance structure. The Company has

embedded ESG requirements into the entire process including Board of Directors' supervision specialized committee

deliberation management execution and functional department implementation. This has gradually formed a closed-

loop ESG system with clear responsibilities a complete chain and top-down integration providing institutional support

for the Company's high-quality and sustainable development.BGI Genomics' ESG structure

Supervise material ESG-related matters of the Company

Review relevant proposals submitted by the ESG Committee

Board of Directors

Review strategic plans systems and working rules related to sustainability and ESG

Monitor and study ESG-related laws regulations and policies

Environmental Social

and Governance (ESG) Review ESG-related disclosure documents including the annual ESG report

Committee Monitor material ESG risks and opportunities and provide recommendations BGI Genomics was honored with the ChinaFund "2025 China Listed Companies Yinghua Award – A-share ESG

Demonstration Case"

Linking ESG performance with senior executive remuneration

BGI Genomics has formulated and improved the Remuneration Management System for Directors and

Organize and implement matters approved by the Board of Directors Senior Management linking the remuneration of directors and senior management with the Company's

long-term interests and sustainability. The performance-based remuneration of senior management is

Promote the integration of ESG requirements into business operations and tied to annual operating performance and individual performance evaluations. Furthermore a clawback

Management management mechanism for remuneration strengthens constraints on governance risk behaviors such as major

violations of laws and regulations and financial fraud.Provide ESG-related information

Functional departments Implement specific measures based on actual business needs

business units and

subsidiaries

13 14BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Special Intelligently Shaping the Future of

Topic Genomics Genetic digital intelligence strategy

Empowering a New Ecosystem of BGI Genomics regards artificial intelligence and digital intelligence as important engines for its strategic transformation

Precision Medicine with Digital Intelligence and upgrading. Centered on the overall concept of "generative biological intelligence" the Company continuously explores new paths to enhance the efficiency of life data insight and application through intelligent means. In terms

of its strategic path the Company has established an implementation pathway of "technological innovation – product

In accordance with the Working Rules of the Board of Directors' Environmental Social and Governance (ESG) Committee launch – large-scale operation" centered around the "ALL Plan." It adheres to a product strategy of "large models +

BGI Genomics has established and continuously improved its sustainability governance structure. The Company has vertical applications" to form a sustainable competitive advantage and long-term growth momentum.embedded ESG requirements into the entire process including Board of Directors' supervision specialized committee

deliberation management execution and functional department implementation. This has gradually formed a closed- iGeneT Pro: Promoting quality and efficiency in end-to-end gene interpretation

loop ESG system with clear responsibilities a complete chain and top-down integration providing institutional support

for the Company's high-quality and sustainable development. BGI Genomics continues to advance the deep integration At the clinical application level BGI Genomics has launched iGeneT Pro a professional-grade intelligent interpretation

of "gene technology + artificial intelligence" and expand its layout in "generative biological intelligence." Building on its platform for genetic testing. This platform promotes the evolution of genetic testing from traditional multi-step

existing capabilities in genetic testing genetic counseling and health management the Company further enhances its serial operations to an integrated model of "file upload – intelligent analysis – report generation – expert review." The

AI product matrix by focusing on a multimodal large model for genetic testing an end-to-end intelligent interpretation platform can perform multi-level bioinformatics analysis for SNV CNV and SV and supports single sample upload

platform a genetic counseling assistance system research support tools and ecosystem connectivity. This promotes the batch upload re-analysis and re-inference. Combined with AI-powered variant quality control evidence integration

upgrade of AI from single-point tool applications to multi-scenario full-process collaborative empowerment. With the automated interpretation and explainable decision-making capabilities it reduces repetitive manual labor and

GeneT multimodal large model for genetic testing as its foundational capability the Company continues to expand its improves interpretation efficiency. Clinical validation results show that iGeneT Pro has accumulated a similar case

products and solutions including iGeneT Pro ChatGeneT GeneT Agent GeneT Studio and GeneT API gradually forming library achieving a 99.8% recall rate for the top 30 prioritized variants in over 30000 clinical validations. In terms of

an intelligent system that covers clinical interpretation counseling assistance research support data governance and quality control the accuracy for SNP and Exon CNV quality control has reached 99.3%.capability output. iGeneT Pro core applications and advantages

BGI Genomics' digital intelligence product matrix

Genetic analysis and genetic counseling

End-to-end gene interpretation system:

A one-stop service from variant analysis

to intelligent reporting

Customized report * Routine reports can be fully generated

iGeneT Pro ChatGeneT GeneT Agent GeneT Studio GeneT API interpretation solutions Proprietary model trainingend-to-end by iGeneT Pro while complex

End-to-end gene Genetic counseling Genetic Counseling Agent Comprehensive solutions API & plugins reports require expert reviewComprehensive variant Develop customer-

interpretation platform assistance system interpretation report system based proprietary models using

Bioinformatics algorithm Digital intelligence- Task decomposition Digital intelligence- Capability API calls on population characteristics exclusive data to optimize

acceleration based information assisted reading clinical indications and regionally adapted analysis

summarization Data retrieval Flexible plugin access personalized needs results

Digital intelligence-based Assisted data cleaning

variant quality control Information retrieval MCP access Integration with hospital

Clinical data governance systems

Locus rating Full-process consultation Information aggregation Literature evidence Private medical data

Customized solutions Connecting hospital- integration warehouse constructionenhancement

In-depth interpretation side data

and reasoning Intelligent AI rating capability: Rapid establishment

recommendations Systematic extraction of of customized case

Report personalization ACMG standard evidence knowledge bases based on

items. Rating platform: a standardized clinical data

Rating review and governance system

governance platform

GeneT multimodal large model for genetic testing Rating database: 500000 Core servicegenomic variants

15 16BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

ChatGeneT: Genetic counseling assistance system and talent cultivation tool GeneTAgent:Intelligent agent for

genetic analysis scenarios

To address pain points in genetic counseling such as talent shortages decision-making overload information fragmentation

outdated knowledge and weak follow-up management BGI Genomics continuously improves the ChatGeneT genetic The GeneT Agent is capable of task decomposition

counseling assistance system promoting the empowerment of large intelligent models across all stages of consultation— database retrieval consultation enhancement self-

before during and after. The system supports pre-consultation with a patient-facing large intelligent model automatic reflection and pathogenicity analysis. It can call

extraction of test results and generation of structured consultation checklists. For doctors it offers functions like knowledge upon GeneT-related scenario capabilities in a one-

queries consultation assessment treatment suggestions and communication advice helping to improve consultation stop manner identify user needs through task-based

efficiency and quality. Additionally ChatGeneT can support re-analysis of genetic testing reports similar case queries and decision-making conduct personalized consultations

educational training scenarios. The educational version of ChatGeneT assists in doctor training and talent development intelligently detect conflicting data and dynamically

through methods like simulating patient dialogues with a large intelligent model enhancing personalized consultations and optimize automatically retrieve literature evidence

providing multi-dimensional capability assessments further expanding the application boundaries of artificial intelligence in to rate pathogenicity in real time and aggregate

the genetic counseling ecosystem. information from professional databases to meet

Application paradigm of the ChatGeneT genetic counseling assistance system more flexible demands for genetic counseling and One-stop access to the full-scenario interface of GeneT

intelligent analysis.Patients print their own medical Genetic counseling by doctors

Patient medical GeneT Studio & GeneT API: Expanding the boundaries of scientific research and ecosystem empowerment

Patients bring their records are stored in

records to the doctor the HIS system

Traditional GeneT Studio is a solution focused on scientific research and data governance scenarios. It integrates capabilities for

intelligent literature reading rapid data retrieval data cleaning and structured normalization. Through collaboration

Patients seek direct Doctors + multiple knowledge base websites Unstructured data among GeneT Genos and general large language models (LLMs) it supports tasks such as gene–phenotype association

medical consultation

Medical records are automatically Structured medical records storage Research analysis variant pathogenicity assessment historical case mining disease progression prediction and knowledge graph

sent to the patient enriches the patient case library applicationsNew discoveries construction driving the transformation of existing life science data into high-value resources that are usable analyzable

Patients upload based on big and translatable.materials online and AI Similar patient cases data mining

automatically generates provide more evidence for Meanwhile GeneT API as a capability output interface layer further strengthens ecosystem connectivity and hospital-side

treatment suggestions decision-making

ChatGeneT enablement. It supports API calls plugin integration and connections to hospital systems facilitating the embedding of

relevant models and analytical capabilities into the business workflows of hospitals testing laboratories and partners.Patient + Doctor + AI Structured patient case

questionnaire library This enhances product adaptability deployability and scalability reinforcing the development of an open collaborative BGI's Re-

database External analysis digital intelligence ecosystem for precision medicine.knowledge Software

Genetic

bases prediction counseling

training based Educational

Continuous feedback from follow-up results enriches the case library on AI + big data Accuracy of the Genos human genome GeneT + Genos + LLM joint multi-large-model applications foundation model data analysis mechanism

Variant pathogenicity prediction

Multi-omics analysis

(Pathogenic/Benign)

Historical case mining

Multimodal large model for

genetic testing

Gene–phenotype

association

Evo 2 1B

Variant pathogenicity

Human genome foundation assessment

Evo 2 7B model Disease progression

prediction

REVEL+SpliceAI

Knowledge graph

0 0.2 0.4 0.6 0.8 1 construction

General large models

…

Accuracy

ChatGeneT education edition application cases

17 18BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Good Governance for a Solid

Foundation and Steady Progress

BGI Genomics has always regarded high-quality governance as the fundamental guarantee for sound operations and 1

long-term value creation. We are committed to building a solid foundation for development through a standardized and

transparent governance system safeguarding strategic execution with prudent and forward-looking risk awareness

and fostering internal and external trust through honest and credible business ethics. We continuously promote mutual

reinforcement and coordinated enhancement between governance capabilities and development quality. The Company

deeply recognizes that good governance is not only an inherent requirement for lawful and compliant operations but also Corporate governance Risk and compliance management

a key enabler of organizational resilience stakeholder rights protection and sustainable development. The Company will

continue to strengthen its governance foundation and enhance governance effectiveness and accountability to higher

standards providing a solid guarantee for steady long-term progress and the creation of enduring social value. Business ethics

19 20BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Corporate governance

In 2025 the Company held 3 Shareholders' Meetings;

BGI Genomics strictly complies with laws and regulations including the Company Law of the People's Republic of China

the Securities Law of the People's Republic of China and the Code of Corporate Governance for Listed Companies to

establish a robust corporate governance structure and a sound internal control and risk management system ensuring The Board of Directors convened 4 meetings with an average attendance rate of 100%.standardized operations and scientifically informed decision-making.Operation of the "Two Meetings and One Level"

In 2025 BGI Genomics revised institutional documents including the Rules of Procedure for Shareholders' Meetings Board diversity and independence

and the Rules of Procedure for the Board of Directors continuously strengthening the corporate governance system BGI Genomics revised institutional documents including the Working System for Independent Directors the System

in which the Shareholders' Meeting the Board of Directors and senior management perform distinct roles operate for Special Meetings of Independent Directors and the Remuneration Management System for Directors and Senior

in coordination and maintain effective checks and balances. By standardizing mechanisms for meeting convening Management . The Company has continued to synergistically enhance the Board's diversity independence and

proposal deliberation resolution implementation and record retention the Company continues to enhance the professionalism and has continuously optimized the Board composition in terms of gender educational background

legality and compliance of decision-making procedures governance transparency and supervisory effectiveness. industry experience and professional expertise thereby strengthening the Board's comprehensive capacity to identify

Corporate governance structure risks anticipate trends and support strategy. Concurrently the Company has further improved the support system for

independent directors to fulfill their duties enhancing their ability to independently and lawfully perform their roles

ensuring they effectively contribute to decision-making participation oversight and checks and balances and professional

advisory functions thus further refining a standardized and transparent governance mechanism to better safeguard the

Internal Audit and

Shareholders' Meeting Company's overall interests and the legitimate rights of minority shareholders.Audit Committee Internal Control

Department Board of Directors diversification at BGI Genomics Co. Ltd.Nomination Committee

Board of Directors Corporate

Remuneration and Appraisal Committee Name Director category Education/professional title Sector expert

Finance

expert management

Office of the Board of Directors expert

Environmental Social and Governance Wang Jian Chairman Master's degree ? ?

CEO (ESG) Committee Zhao Lijian Director Bachelor's degree ?

Securities Department

Operations and Management Team Li Ning Director Doctorate degree ? ?

Zhu Shida Director Doctorate degree ? ?

Employee

Zhang

representative Bachelor's degree ?

Guocheng

director

Master's degree Chinese Certified

Wang Yujue Director Public Accountant ? ?

Senior Accountant Senior Economist

Independent

Du Lan PhD Senior Economist ? ?

director

Independent

Yu Lisheng Doctorate degree ?

director

Independent

Hou Zhibo Doctorate degree ?

director

2122

Key performance

Support System

Business Unit

Big Data & Intelligence

Business Unit

Precision Medicine

Solution Business Unit

Marketing Regional Theater

Marketing System

Production & Delivery

System

Product R&D SystemBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

In 2025 the Company held 6 specialized committee meetings in total including 4

In 2025 the Company's Board of Directors comprised 9 members including 1 female director

meetings of the Audit Committee; 1 meeting of the Remuneration and Appraisal Committee

accounting for 11.11% of the total; 3 independent directors accounting for 33.33% of the

and 1 meeting of the ESG Committee.total;This year 3 director training sessions were conducted.Board of Directors effectiveness evaluation

Development of specialized committees of the Board of

BGI Genomics continuously improves its Board effectiveness evaluation mechanism advancing Board performance

Directors from standardized operation toward efficient and accountable fulfillment of duties. This consistently enhances

In accordance with internal institutional documents such as the Working Rules for the Audit Committee of the Board capabilities in scientific decision-making professional oversight and strategic leadership laying a solid foundation

of Directors the Working Rules for the Nomination Committee of the Board of Directors Working Rules for the for elevated corporate governance and sustainable development. the

Remuneration and Appraisal Committee of the Board of Directors and the Working Rules for the Environmental Social

and Governance (ESG) Committee of the Board of Directors BGI Genomics enhances the depth of research and quality BGI Genomics' director evaluation methods and practices

of decision-making by the Board on matters such as financial review talent selection remuneration incentives and

sustainability. This is achieved by clarifying the responsibilities and operational protocols of specialized committees— All directors conduct a self-evaluation of their performance at year-end

including audit nomination remuneration and appraisal and ESG—thereby promoting more refined prudent and Self-evaluation

of directors' Non-independent directors prepare the Annual Report on the Work of the Board of Directorsefficient board governance.performance Independent directors prepare the Independent Directors' Debriefing Report and present it at

the annual Shareholders' Meeting

Functions of BGI Genomics' specialized committees

Formulate selection Comprehensive The Board combines self-assessment materials with actual performance throughout the yearReview financial criteria and procedures company

information and its evaluation Focus on meeting attendance proposal deliberation and provision of professional for directors and senior recommendations

disclosure management

Supervise and evaluate Nomination Screen review and make

internal and external Audit Committee Committee recommendations on

audit activities and candidates and their

internal controls Performance evaluation of Evaluate the operational performance of the Audit Committee Nomination Committee qualifications

specialized Remuneration and Appraisal Committee and ESG Committee

committees Focus on their roles in proposal deliberation oversight and decision-support functions

Formulate appraisal Review sustainability

standards for directors strategies policies and

and senior management Remuneration ESG Committee disclosure documents Conduct evaluations based on internal systems such as the Working System for

Review remuneration and Appraisal Monitor ESG risks

Committee Independent Directors and the System for Special Meetings of Independent Directorspolicies decision-making and opportunities System and

resource Strengthen performance incentives and constraints through the Remuneration processes and clawback and provide assurance Management System for Directors and Senior Management

arrangements recommendations Regularly organize directors to attend external training sessions hosted by the SZSE and

the Shenzhen Public Companies Association to enhance performance capabilities

2324

Key performance

Key performanceBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Investor relations management Case Conducting investor engagement activities to enhance market communication and

study value recognition

In accordance with legal and regulatory documents such as the Guidelines for the Management of Investor Relations

of Listed Companies and the Company's Articles of Association BGI Genomics has formulated institutional In February 2025 BGI Genomics hosted a research visit by Goldman Sachs and overseas institutional investors.documents including the Investor Relations Policy the Information Disclosure Policy the Internal Reporting System Company management provided a systematic overview of its core business layout technological innovation

for Material Information and the Registration and Filing System for Insiders of Inside Information. The Company progress exploration of intelligent large model applications and future growth directions and engaged in in-depth

continuously refines its investor relations and information disclosure management mechanisms constantly discussions with investors on operational performance. This visit enhanced the capital market's understanding of

enhancing its ability to communicate transparently and respond appropriately to the capital market. the Company's strategic transformation and long-term development logic improved transparency in information

Meanwhile the Company adheres to the principles of compliance equality proactivity and integrity promoting communication and investor trust and supported the Company's efforts to deepen international market recognition

integrated efforts in investor communication grievance handling information disclosure and shareholder rights and shape its long-term value proposition.protection. This continuously deepens investors' understanding of and confidence in the Company's strategy

operations and governance. The Company strictly implements its information disclosure management system

continuously improves disclosure quality and promptly addresses investor inquiries through multi-channel

communication mechanisms to safeguard investors' right to information and legitimate interests.BGI Genomics' investor relations management system

Principles of compliance equality proactivity and integrity

The Board Secretary serves as the head of investor relations management and is also responsible

for implementing relevant management measures organizing specialized training and monitoring

feedback from media and online channels

BGI Genomics hosts a research visit by Goldman Sachs and overseas institutional investors

The Securities Department is the functional unit responsible for planning organizing and

executing various investor relations activities

Communication targets include investors securities and industry analysts financial media and

other relevant institutions In 2025 the Company held 3 earnings calls 2 online earnings Q&A sessions and 3

Communication content includes development strategy business operations material events

environmental and social governance information cultural initiatives ways to exercise shareholder

rights investor grievance handling and risk challenges online institutional research sessions 2 offline roadshows (including institutional strategy

Communication is primarily conducted via announcements Shareholders' Meetings earnings

calls investor surveys roadshows site visits telephone fax email the Company website and the conferences) and organized or participated in 20 offline research activities.Hudongyi platform

Investor complaints primarily concern matters such as information disclosure corporate

governance and investor rights protection; the Board Office coordinates handling with the Board

Secretary as the responsible officer

The process follows acceptance recording verification and investigation formulation of handling

opinions and response to the complainant. Handling is completed within the prescribed

timeframe and a classified ledger is maintained for archiving

For improperly handled matters or those involving illegal acts accountability is enforced per

the accountability mechanism; disputes are resolved through third-party mediation or legal

proceedings when necessary

2526

Key performance

Management Management Communication Communication

principles responsibilities parties and content channels Complaint handlingBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Risk and compliance management BGI Genomics' internal control development and management measures

BGI Genomics places great emphasis on risk management and compliant operations. The Company continuously

enhances its integrated risk and compliance management system covering risk identification compliance control · F ormulate the Internal Control Development Plan and Program to clarify

Launch and

audit supervision and corrective improvement. Legal and compliance requirements are embedded throughout the implementation background scope work plan and other elements planning serving as the basis for subsequent activities and establishing the internal

governance decision-making business operations and employee conduct. Adhering to the principles of prevention control organizational structure.first balanced control and continuous improvement the Company steadily strengthens its capabilities to

identify respond to and remediate various operational and compliance risks promoting synergistic deepening of

standardized operations and sound business practices thereby establishing a robust governance foundation for

high-quality development.Internal

Risk management · B ased on the Basic Standard for Enterprise Internal Control and its control supporting guidelines; review

· C omprehensively review the Company's policies and conduct interviews

BGI Genomics continuously refines its compliance and internal control system covering risk identification audit with all business departments.supervision and corrective improvement. Risk management requirements are integrated into the entire process of

governance decision-making and business operations. The Company adheres to the principles of prevention first

balanced control and continuous improvement steadily enhancing its ability to identify respond to and remediate

operational risks thereby establishing a solid governance foundation for high-quality development.Identifying · Drawing on best practices and the Enterprise Internal Control Guidelines

Risk management governance structure internal methods such as benchmarking interviews process mapping and

control walk-through testing are used to assess the design and operational

deficiencies effectiveness of control measures and identify control deficiencies.In accordance with institutional documents such as the Internal Control Management Policy and the Internal Audit

Management Policy BGI Genomics has established an internal control system covering all business processes. It

regularly conducts internal control evaluations and audits and drives closed-loop rectification of identified issues.Risk management requirements are embedded into strategy governance and daily operations. Systematic internal

control procedures and necessary internal oversight mechanisms are implemented from the corporate level down

to individual business processes. The Company has established an Internal Audit and Internal Control Department · I n response to identified internal control deficiencies the internal

responsible for managing evaluating inspecting and supervising internal control activities reporting directly to the control team proposes improvement recommendations for the issues Formulation and

Board of Directors and the Audit Committee. found clearly defining implementation steps and the relevant personnel implementation

involved. These recommendations are tracked for rectification after of rectification

approval by the responsible manager. plan

Risk management mechanism

BGI Genomics continuously enhances its risk management and internal control framework organically integrating

risk identification process control supervision and evaluation and cultural development. The Company promotes

the integration of compliance requirements into daily business management steadily improving standardized

operational capabilities and sound development performance thereby providing assurance for stable operations

and high-quality growth.

27 28BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Compliant operation Compliance and internal control culture building

BGI Genomics consistently treats compliance culture building as a critical foundation for enhancing governance

BGI Genomics continuously enhances its compliance management strengthening risk defenses and ensuring sound operations. The Company continuously reinforces organization-

system covering compliance control corrective actions and wide compliance and accountability awareness fosters a positive environment of knowing observing and applying

continuous improvement. Guided by the principles of "good regulations and steadily improves its capacity for lawful and compliant operations providing a solid foundation for

governance applicability integrity transparency accountability high-quality development.and sustainability" and the policy of "lawful compliance ethical The Company regularly disseminates compliance cases industry briefings and related content through its

operations; full participation continuous improvement" the "BGIlianjie" (BGI Integrity) WeChat official account releases integrity and compliance-themed posters during

Company steadily strengthens its ability to identify respond to holidays and organizes compliance training at headquarters and regional offices to reinforce organization-wide

and remediate compliance risks promoting synergistic deepening compliance awareness through multiple dimensions.of standardized operations and sound business practices. In 2025

the Company successfully passed its recertification audit with an BGI Genomics is certified to the ISO 37301 Case Participating in global compliance summits to exchange cutting-edge practices and study strengthen compliance governance capabilities

outstanding result of "zero non-conformities." compliance management system

In April 2025 BGI Genomics participated in the "China Global

Compliance management mechanism Compliance Summit 2025" held in Shanghai engaging in exchanges and learning on frontier topics including evolving international

business environments corporate governance and sustainability ESG

In accordance with the Compliance Management Manual the Company has established a comprehensive compliance compliance ethical compliance culture international compliance

management system integrating compliance requirements into its strategy governance and daily operations and management systems data security and compliance cross-border

continuously enhancing its standardized operational capabilities and sound development performance. investment compliance risk mitigation and digital implementation

of compliance. This enhanced the Company's understanding of

BGI Genomics' compliance management measures international compliance trends standard frameworks and regulatory

changes providing strong support for continuously refining its internal

compliance system deepening compliance culture and strengthening

Compliance objective management Risk identification and assessment sound operational capabilities. BGI Genomics participated in the China Global

Compliance Summit 2025

Periodically review laws and regulations

Decompose monitor and track annual in accordance with ISO 37301 compliance

compliance objectives management system requirements

Focus on management effectiveness regarding Identify compliance obligations and risks in

major penalties risk handling and incident conjunction with business activities establish

response In 2025 the Company conducted 27 compliance training sessions;a Compliance Risk Repository and develop

categorized response measures

The number of incidents involving major public opinion crises or losses exceeding 0.5%

Monitoring evaluation Compliance culture building

and continuous improvement of the Company's annual revenue (based on audited revenue from the most recent fiscal

Continuously evaluate system effectiveness Promote compliance culture based on policies

year) due to administrative penalties was 0;

through monitoring and measurement such as the Employee Code of Business Conduct

internal audits management reviews and goal and Prohibited Employee Conduct The timely handling rate for high-compliance-risk cases the response rates for information

achievement assessments Continuously reinforce organization-wide

Dynamically track and improve responses to compliance awareness through new-hire

security incidents compliance incidents and legal proceedings were all 100%.high-compliance-risk situations and compliance orientation compliance training ISO 37301 all-

incidents staff examinations internal compliance training

and external seminars and exchanges

2930

Key performanceBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Business ethics Additionally to identify and prevent conflicts of interest between employees and the Company mitigate management risks protect mutual interests uphold internal fairness and prevent corruption the Company requires

employees to declare and update their conflict-of-interest status. The Company uses holistic data analysis to identify

BGI Genomics has established institutional documents including the Anti-Fraud Management Policy the Anti- at-risk individuals strengthens supervision and control continuously enhances employee integrity awareness

Corruption and Anti-Commercial Bribery Management Policy the Conflict of Interest Management Policy and the and deepens its corporate integrity culture. During the reporting period the completion rate for conflict-of-interest

Integrity Agreement . The Company continuously refines its integrity management system covering governance declarations was 100%.business operations and employees. Adhering to a "zero tolerance" governance approach it integrates integrity

into systems processes oversight and accountability mechanisms steadily strengthening end-to-end anti- Whistleblowing and whistleblower protection

corruption governance capabilities—from preventive measures at the source and process controls to outcome-based BGI Genomics has established the Whistleblower Protection and Reward Policy maintaining open internal and

accountability—and continuously reinforcing business ethics to build a robust integrity firewall. external reporting channels and strengthening the acceptance investigation handling and feedback on corruption

Anti-commercial bribery and anti-corruption system and non-compliance leads striving to build a supervisory ecosystem where whistleblowers feel safe to report investigations are thorough actions are stringent and protections are robust. Through arrangements such as

BGI Genomics has always upheld the principles of transparent operations and ethical conduct establishing direct investigation by the Internal Audit and Internal Control Department strict confidentiality of whistleblower

a comprehensive anti-commercial bribery and anti-corruption system covering all employees and upstream/ information and zero tolerance for retaliation the Company further enhances the timeliness of issue detection and

downstream partners. Through four key measures—system development supervision and control training and the credibility of its oversight mechanisms.communication and whistleblower protection—the Company continuously enhances its anti-commercial bribery BGI Genomics' end-to-end whistleblowing acceptance investigation handling and feedback

and anti-corruption management framework. mechanism

BGI Genomics' anti-commercial bribery and anti-corruption system Multi-channel acceptance

Multiple reporting channels are available to employees

Core Zero tolerance suppliers distributors customers and other partners

principles Equal emphasis on prevention and

punishment Closed-loop feedback Standardized registration and

Internal and external collaborative on outcomes acceptance

oversight

For real-name reports the Reports must be fact-based. While

whistleblower is informed of real-name reporting is encouraged

Governance Anti-Fraud Management Policy investigation and handling anonymous or pseudonymous

level Internal Audit Management System outcomes within 3–6 months reporting is permitted to respect the

Internal Control Management Policy depending on case progress whistleblower's preference

Anti-Corruption and Anti-Commercial Case handling is linked with Whistleblowers should provide as corrective actions and internal much information as possible about

Bribery Management Policy control improvements to the reported individual violation facts

establish a closed-loop oversight evidence and valid contact details

BGI Genomics was honored as an "Excellent Supporting Unit"

by the Enterprise Anti-Fraud Alliance in 2025 system For real-name reports the Internal

Audit and Internal Control Department

Business Integrity Agreement responds with acceptance status within

level Conflict of Interest Management Policy Categorized handling and 3 days of receipt; for anonymous

Partner integrity clauses accountability reports an investigation is initiated within 3 days of receipt

For verified reports violators will be subject to

appropriate disciplinary action Independent investigation and verification

Violators will be held accountable in

Employee Employee Code of Business Conduct accordance with policies such as the Cadre The Internal Audit and Internal Control Department is the

level Prohibited Employee Conduct Accountability Policy the Employee Handbook Company's designated unit authorized to investigate acts and the Employee Disciplinary Regulations. of corruption reporting directly to the General Manager

Commitment training and Cases involving suspected criminal activity It conducts investigations and verifications on reported

accountability mechanisms will be referred to judicial authorities for legal matters ensuring the independence and integrity of the

proceedings acceptance and investigation processes

31 32BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

BGI Genomics reporting channels BGI Genomics' business partner integrity control mechanism

Reporting channels

Report via WeChat Official Account: "BGIlianjie" Business partner Business partner In-contract Issue resolution

onboarding engagement management and closed-loop

Report by phone: 0755-36307270 improvement

Report by email: P_IA@genomics.cn Make integrity Sign the Integrity Conduct on-site integrity Strict handling of

commitment a Agreement and embed awareness visits violations internal

Report by mail: East I Zone 9F Main Building BGI Center No.9 Yunhua Road Yantian District Shenzhen China prerequisite for integrity clauses in Issue integrity reminders notifications and warning

partnership contracts Administer integrity education enhancement Report in person by appointment perception surveys of business partner onboarding mechanisms

Other methods deemed appropriate by the whistleblower implementation of in-

depth background

checks and upgrading

of system audit trail

BGI Genomics whistleblower protection policy capabilities

Strict confidentiality Strict prohibition of Special protection Protection of reporting Partner protection Case

management retaliation for identified rights mechanism study Participating in the Youth Integrity Salon to build consensus on integrity governance

whistleblowers

Whistleblower identity Any form of direct Implement special Enhanced protections Partners who

information and indirect or retaliatory protective measures for internal proactively report and In April 2025 BGI Genomics was invited to participate in the "Youth Voices on Integrity" ESG-themed salon. The

reporting materials are action is explicitly for identified whistleblowing actively cooperate Company engaged in in-depth discussions with corporate representatives professional institutions and media on

kept strictly confidential prohibited whistleblowers employees regarding with investigations topics including integrity risk prevention for young employees corporate anti-fraud system development and ESG

Breaches of Such behaviors will be Dedicated personnel reward disbursement will be protected in

confidentiality will be dealt with seriously in manage information job transfers etc. accordance with laws requirements. This event helped broaden the Company's perspective on integrity governance promoting synergistic

rigorously investigated accordance with laws coordinate Prevent adverse and regulations efforts among institutional constraints technological safeguards and cultural guidance thereby offering valuable

and held accountable and regulations communications and consequences arising Relevant liabilities insights for cultivating an ethical workplace environment for young professionals and reinforcing the foundation for

implement protections from whistleblowing may be mitigated or

waived depending on sustainable development.circumstances

Anti-corruption culture building

The Company emphasizes integrity culture promotion and integrity awareness education standardizing employees'

ethical mindset and conduct from the outset. It comprehensively strengthens integrity culture through various

approaches including new-hire and specialized training participation in integrity and compliance conferences

dissemination of integrity reminders via its official account and organizing integrity education and promotional

activities.Supervision of business partners

BGI Genomics continuously extends its integrity requirements to suppliers distributors and other partners.Through arrangements such as pre-engagement commitments in-contract constraints on-site visits for awareness

promotion questionnaire surveys and corrective actions it advances partner integrity management from

contractual obligations toward full-process collaboration. The Company regards business partner compliance

management as a critical extension of its business ethics framework consistently fostering a cooperative ecosystem "Youth Voices on Integrity" ESG-themed salon

grounded in transparency integrity mutual trust and shared success.

33 34BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Case Building an integrity dialogue platform to foster industry-wide co-governance BGI Genomics' anti-monopoly and fair competition risk control measures

study consensus

In 2025 the "Integrity Ecosystem Empowering the Development of the Biopharmaceutical Technology Industry

Exchange Meeting" hosted by BGI Genomics and co-initiated with support from the Enterprise Anti-Fraud Alliance

was successfully held at the Spatio-Temporal Center attracting representatives from 23 leading biopharmaceutical

technology companies. The meeting featured in-depth exchanges on building an integrity ecosystem analyzing Institutional norms Risk identification

industry trends and innovating practical approaches facilitating experience sharing and consensus-building

among enterprises and providing strong support for addressing integrity governance challenges and promoting Clarify fair competition management Identify risks in key scenarios such as competitive

standardized healthy industry development. requirements and behavioral boundaries based conflicts improper benefit transfers misuse of

on policies such as the Conflict of Interest insider information and role conflicts

Management Policy

In-process control

Declaration and approval In-process control

Establish onboarding proactive and annual Continuously strengthen control over key risk

Group photo of the Integrity Ecosystem Empowering the Development of the Biopharmaceutical Technology Industry Exchange Meeting declaration mechanisms to enhance dynamic items through cross-departmental review

management of conflict-of-interest matters remediation tracking and information

confidentiality

In 2025 the Company conducted 13 anti-commercial bribery and anti-corruption training sessions

with 828 participants; The signing rate of the Compliance Commitment Letter by all employees was

100% and the signing rate of the Integrity Agreement by suppliers was 100%.

Oversight and feedback Accountability and enforcement

Business ethics audit and oversight

Maintain open consultation and reporting Strictly address undeclared unremediated or

Regarding internal audits of business ethics the Company's Internal Audit and Internal Control Department channels promptly accept verify and drive non-compliant behaviors in accordance with

focuses on ethical practices in business decision-making employee conduct supply chain management and closed-loop resolution of issues laws and regulations to reinforce institutional

anti-corruption. During the reporting period internal audit results demonstrated the Company's outstanding constraints

performance in business ethics. Both management and employees strongly endorsed and voluntarily adhered to

relevant requirements providing robust support for internal controls and sustained sound development.Anti-monopoly and fair competition management

BGI Genomics strictly complies with the Anti-Unfair Competition Law of the People's Republic of China the Anti-

Monopoly Law of the People's Republic of China and related regulations and standards. It has established the In 2025 no incidents of unfair competition occurred within the Company.Employee Code of Business Conduct Prohibited Employee Conduct and Conflict of Interest Management Policy

continuously integrating fair competition principles into employee conduct standards conflict-of-interest prevention

and partner management. The Company has built clear institutional boundaries to prevent unfair competition

focusing on integrity intellectual property protection insider information safeguards and avoidance of competitive

conflicts.

3536

Key performance

Key performanceBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Quality First Intelligence for Life

Guided by the mission "Omics for All" BGI Genomics upholds the public health principle of "prevention over

cure accessible to all" for inclusive and precise disease prevention and control. The Company deeply integrates

technological innovation with global expansion driving genomics innovation in precision medicine through new 2

models and technologies. Committed to breaking down geographical barriers BGI Genomics strives to make genetic

testing fairly accessible worldwide transforming scientific innovation into an inclusive force for health equity and

contributing enduring momentum to the global community of health for all. To achieve this the Company has built

a comprehensive quality management system ensuring end-to-end quality control to safeguard human health

and safety through genomics. It has also innovated a digital customer service platform leveraging rapid-response Product safety and quality Innovation-driven development

mechanisms and encrypted privacy data to simultaneously enhance service value and customer trust. Furthermore

the Company deepens green supply chain development collaborating with upstream and downstream partners to

build a resource-efficient environmentally friendly industrial ecosystem. With an open approach it promotes co- Supply chain management Customer service

development of industry standards and technology sharing leading synergistic advancement in the bioeconomy era

so that the benefits of scientific progress reach every life. Data security and customer privacy Industry collaboration

37 38BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Product safety and quality

The Company places paramount importance on the quality management of its products and services steadfastly

adhering to the principle that "to lead the industry one must first lead in quality." Grounded in the unique Management system

characteristics of the life sciences field it has established a clear quality strategy and rigorously follows the quality

policy of "impartiality scientific rigor accuracy and timeliness." By formulating core policies including the Quality BGI Genomics places exceptional emphasis on quality management treating quality as its lifeblood. It adheres to the

Management Manual Product Quality Control Procedures and Adverse Event Handling Procedures the Company principle "to lead the industry one must first lead in quality" and strictly follows the quality policy of "impartiality

has achieved comprehensive quality coverage across the entire product life cycle. scientific rigor accuracy and timeliness." The Company has received numerous domestic and international

quality awards with its quality achievements widely recognized by third-party institutions. According to data

Governance from accreditation bodies and industry peers BGI Genomics is among the few organizations in gene sequencing covering reproductive health oncology infectious disease and multi-omics big data and simultaneously holds

comprehensive accreditations including ISO 13485 ISO 15189 ISO/IEC 17025 CMA ISO 37301 ISO/IEC 27001 ISO

Governance structure 9001 ISO 14001 and ISO 45001. It was also the first institution in China's high-throughput gene sequencing sector

to obtain ISO 15189 ISO/IEC 17025 ISO/IEC 27001 and ISO 37301 accreditations. During the reporting period its

BGI Genomics' product quality governance structure operates under Board oversight with top management—led by subsidiaries continued participating in domestic and international proficiency testing programs including those

the CEO—defining the quality strategy. An independent Compliance and Quality Department has been established from the National Center for Clinical Laboratories (NHC) and the European Molecular Genetics Quality Network

to implement end-to-end quality management standards while functional departments fulfill their respective (EMQN) achieving perfect scores in over 800 tests and maintaining leadership in laboratory testing quality.responsibilities to ensure product quality.BGI Genomics' product quality governance structure BGI Genomics' comprehensive quality management framework

Occupational health and safety

management system Quality management system

Environmental management

Board of Directors systemISO 45001:2018 ISO 9001:2015 ISO 14001:2015

Information Security

Management System Level III Classified Protection

Personal information

ISO/IEC 27001:2022 of Information Security

management system

ISO/IEC 27701:2019

CEO

Medical device quality Medical laboratory quality Information Security

management system management system Management System

ISO 13485:2016 ISO 15189:2022 ISO/IEC 27001:2022

Office of the Board of

Audit Committee Customer Scientific and Directors Medical Devices Medical services technological Customer needs services satisfaction

Mandatory Medical device registration/filing certificates medical device manufacturing/

thresholds distribution licenses medical institution practice licenses biosafety filings

Supply chain Product R&D Production & Sales & after- Compliance & Support & PCR filings human genetic resources filings proficiency testing etc.functional functional delivery sales quality safeguard

departments departments functional functional functional functional Compliance management systemdepartments departments departments departments ISO 37301:2021

3940

Continuous improvement of qualityBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Strategy

BGI Genomics has always regarded product quality and safety as the cornerstone of its business operations and

sustainable development. The Company continuously evaluates the impact of quality management activities—

spanning R&D production delivery and service—from a full-life-cycle risk prevention perspective on compliant

operations customer trust brand competitiveness and long-term growth. It integrates end-to-end quality

governance capability with technological innovation and business scale-up evolving quality management from

baseline compliance assurance toward enhanced operational resilience brand value creation and leadership in

high-quality industry development.Risk/ Impact

Specific description Financial impact Response strategy

Opportunity duration

Core risk

BGI Genomics certified to ISO 9001 quality management BGI Biotechnology (Wuhan) Co. Ltd. certified to ISO 13485

system medical device quality management system

Key stages—including gene sequencing May increase costs related

analysis interpretation and report to review rectification

Implement standardized end-

Compliance issuance—demand high levels of Short-to- customer communication

to-end operations and multi-

risks in test stage review mechanisms

results and professionalism and standardization. medium

and compliance

Inadequate management and review term management and

enhance closed-loop report

reports may affect test result accuracy report exert pressure on brand

recall management and

reputation and business strengthen error control across compliance and customer trust. expansion. all processes.The R&D production delivery and after- May increase costs

sales chain is long and requires high related to rework quality Strictly implement core quality

Full life coordination. Deficiencies in quality Medium- improvement and management systems achieve

cycle quality standard execution and process control and operational coordination full life-cycle quality control

control risks may affect product/service stability long- and exert pressure on coverage and conduct regular

customer experience and operational term market trust and business internal quality audits and

efficiency. stability. inspections.BGI Genomics certified by CMA Wuhan BGI Technology Service Co. Ltd. Wuhan BGI Clinical Laboratory

accredited to ISO/IEC 17025 accredited to ISO 15189

Core opportunities

External quality management awards

Continuously refine the end-to-end Deepen the quality strategy

Opportunities to quality control system to deliver highly Medium- Reduced losses from

enhance quality reliable and compliant products and and quality incidents

build a high-quality end-to-end

control system and strengthen

brand and market services strengthen customer trust long- enhanced customer loyalty

In the Tianjin Binhai New Area Quality Improvement Competition won 3 competitiveness and brand reputation solidify industry term and brand premium and

core brand competitiveness

sustained revenue growth. through compliant operations

first prizes 2 second prizes 10 third prizes and 10 excellence awards; leadership and expand market share. and superior service.At the Shenzhen Quality Management Group Trustworthy Team

Achievement Exchange and Training Conference won 1 gold 1 silver 2 Opportunities Through quality initiatives

bronze and 4 excellence awards for QC groups; for quality Encourage quality innovation

enhancement technical optimization and process improvements the Company can Short-to- Reduced quality costs such and technical breakthroughs In Wuhan Quality Association QC group activities won 4 third prizes; cost

In Hebei Province QC group activities won 1 second-class achievement reduction and effectively reduce retesting rates error medium

as rework and retesting conduct regular QC group

rates and quality losses enhancing term and enhanced business activities and institutionalize

award. operational capacity and profitability. quality improvements into efficiency operational efficiency and lowering

improvement quality-related costs.standardized processes.

41 42BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Impact risk and opportunity management

R&D pilot trial Focused on pilot and small-scale trials enhancing product traceability and documentation

and traceability

The Company emphasizes risk management for its products and services regularly conducting risk identification management compliance through optimized coding document completion test/process optimization requests

analysis evaluation and treatment to control risks affecting test result quality and patient safety thereby preventing enhancement and feedback on documentation issues ensuring efficient R&D and pilot-scale advancement

and mitigating adverse impacts and potential issues. Additionally it has established a quality objective and indicator

monitoring system. By regularly tracking deviations from control limits it monitors QMS performance analyzes

data trends to promptly detect anomalies and implements preventive actions. To ensure the continued adequacy Core product

and effectiveness of the QMS the Company employs a multi-dimensional oversight mechanism—including routine process For the NIFTY extraction kit production process used technical control tools to optimize liquid optimization dispensing in buffer preparation and post-aliquoting packaging reducing cumulative production errors

inspections unannounced audits and system reviews—and drives continuous improvement through the PDCA (NIFTY extraction by 80% significantly improving dispensing accuracy and increasing production efficiency 20-fold

cycle. kit)

Indicators and targets Core product

process For the NIFTY sequencing kit production process optimized staffing and workflow reducing

optimization

(NIFTY personnel by one in the sample loading plate aliquoting step increasing aliquoting efficiency by 24%

sequencing kit) and decreasing per-kit production time by approximately 2.5%Quantitative indicator disclosure item Unit 2025 data

Product conformity rate % 99.5 Case study Quality Control (QC) group activities

From April to November 2025 the Company organized a seven-month BGI Genomics Quality Control (QC) Group

activity centered on the core goal of "full participation and continuous improvement." Following the PDCA (Plan-

Product quality improvement initiatives Do-Check-Act) cycle and systematically applying quality management theories and statistical methods the initiative

engaged employees throughout the entire quality improvement and innovation process. This activity effectively

To continuously strengthen product quality foundations and enhance operational and R&D efficiency the Company enhanced organization-wide quality awareness and delivered tangible results in reducing quality costs and

systematically advanced quality improvement initiatives across five dimensions: production site compliance end- improving production efficiency and economic returns driving continuous advancement in the Company's quality

to-end standardization management efficiency R&D traceability and core product processes. Through targeted management capabilities.optimizations significant improvements were achieved in production compliance operational standardization

management efficiency and core product output. Concurrently Quality Control (QC) group activities further

reinforced the end-to-end quality assurance system.Product quality improvement measures

Production site Optimized eight types of production labeling and workshop layouts to improve compliance and

and compliance space utilization effectively reducing contamination risks Quality Month – Tianjin Group photo of the Integrity Ecosystem Empowering the Development management of the Biopharmaceutical Technology Industry Exchange Meeting

optimization

End-to-end Achieved efficient standardized end-to-end production control through 10 improvements including

standardized dedicated equipment deployment optimized consumable selection and aliquoting processes and

production control standardized operating procedures

Management process Introduced intelligent office tools and optimized issue collection mechanisms and document templates

and office efficiency to streamline information flow enable closed-loop issue management and standardize record-keeping

enhancement comprehensively enhancing production and quality management efficiency Quality Month – Pipetting Competition Quality Month – Knowledge Quiz

43 44BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

End-to-end closed-loop quality testing and control mechanism Medical device vigilance management

The Company has established a closed-loop quality testing and control mechanism covering all processes and Medical device vigilance is a core component of the Company's full life-cycle quality management and a key measure

nodes—pre-analytical analytical and post-analytical—throughout the full life cycle of medical testing services. to protect public safety in medical device use and fulfill its social responsibility in healthcare. The Company strictly

This mechanism implements standardized and refined controls over all factors affecting test result accuracy aligns with domestic and international regulations and standards including the Regulations for the Supervision and

comprehensively ensuring the compliance accuracy and reliability of test results. Administration of Medical Devices and the Measures for Monitoring and Re-evaluation of Medical Device Adverse

Events . It has established core management procedures such as the Post-Market Surveillance Control Procedure

Vigilance System Control Procedure and Medical Device Adverse Event Monitoring and Re-evaluation Control

Procedure clearly defining management requirements execution standards and role responsibilities across the

Pre-analytical process quality control entire process—including adverse event collection monitoring/reporting investigation/analysis risk evaluation

control/measures product re-evaluation and system audit/optimization. This institutionalizes proceduralizes and

Focus on the testing origin by standardizing the entire process—from test ordering and sample collection to standardizes end-to-end vigilance activities providing robust policy and systemic support for compliant operations.transport and receipt—with clear operational protocols and acceptance/rejection criteria to ensure sample

compliance and integrity from the outset rigorously controlling quality at the testing entry point. Medical device vigilance system

The Company strictly complies with domestic and international medical device regulatory requirements prioritizes

Analytical process quality control product safety risk management and has established and continuously improves a medical device vigilance

management system covering the entire post-market life cycle.Anchor core testing stages and establish multiple quality defense lines. Rigorously validate and verify testing

methods to ensure clinical suitability. Implement full life-cycle management of instruments reagents Medical device vigilance management structure of BGI Biotechnology (Wuhan) Co. Ltd.and consumables with robust metrological traceability and performance verification to maintain stable

compliant testing conditions. Deploy a dual quality control system combining internal QC and external

EQA for routine process monitoring triggering immediate corrective actions upon anomalies. Enforce strict Responsible for approving adverse event-related management systems;

personnel authorization and competency controls to mitigate operational risks at the source. General Responsible for approving external communications;

Decision- manager Approve investigation and handling reports for adverse events and major

making level quality incidents.Post-analytical process quality control Responsible for developing and refining procedures for adverse event

Quality reporting and monitoring;

Strictly safeguard the result delivery stage and standardize the entire post-analytical process. A rigorous Management Responsible for organizing investigation analysis evaluation and handling

result review and release mechanism ensures all results are reviewed by authorized personnel before Management Department of adverse events;

level manager

issuance. A report management process guarantees immediate clinical notification to protect patient safety. Responsible for periodically organizing internal or external QMS audits

Report corrections and traceability are standardized to tightly control result application risks. Post-analytical covering adverse event monitoring.sample retention and disposal protocols balance retesting/traceability needs with biosafety compliance. Collect adverse event information per procedures and promptly report to

Adverse event drug regulatory authorities;

monitoring Participate in investigation analysis evaluation and handling of adverse Product recall management Execution specialist events and major quality incidents; complete periodic product risk

level

The Company adheres to its quality control baseline by establishing a comprehensive product recall mechanism evaluation reports.and strictly implementing specialized procedures including the Product Recall Management Procedure Recall

Management Procedure and Result Modification and Report Recall Procedure standardizing the closed-loop

Includes heads of core departments—Technical QC Sales Production

operation of recalls. For testing services it has built an end-to-end traceability system centered on sample IDs Heads of Engineering and Supply & Sales—who lead their teams in coordinated

fully recording information across all stages—including submitting units testing workflows report generation relevant

execution of vigilance tasks.and modifications/recalls—achieving full life-cycle traceability from sample receipt through report delivery and Coordination departmentslayer

subsequent handling effectively safeguarding customer rights and service quality/safety.

45 46BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Operation of the medical device vigilance system

The Company fully implements the "Three Proactive" management requirements establishing a multi-channel

comprehensive adverse event information collection network.Adverse event monitoring activities required of medical device registrants

Proactive disclosure of contact information

Disclose contact details including phone mailing address email and fax; designate a

contact person. Individual Group medical Periodic risk Key medical Product re-

medical device device adverse evaluation report device evaluation

adverse event event report monitoring

report report

(Innovative

Proactive collection and reporting products)

Organization and Proactively collect adverse event information from

personnel distributors user facilities and end-users.(Responsibilities)

Medical device vigilance training and management effectiveness

BGI Genomics places high priority on compliance management and professional capability development in

Proactive reporting and evaluation medical device vigilance integrating relevant training into its routine quality management program to continuously

Directly report and evaluate suspected adverse events via the national monitoring enhance compliance awareness and expertise across roles ensuring vigilance requirements are implemented at

information system and submit group incident investigation reports and periodic risk the post level and executed by individuals. In July 2025 the Quality Department of BGI Biotechnology (Wuhan)

evaluation reports as required. Co. Ltd. conducted a specialized training session on Medical Device Adverse Event Monitoring and Re-evaluation

covering supervisors and above from Production as well as staff from Quality Management Technical and Sales

Management departments. The session systematically covered regulatory requirements management systems

operational procedures and role responsibilities comprehensively strengthening participants' compliance execution

capabilities.For post-market medical devices the Company systematically conducts five core monitoring and reporting activities In terms of compliance effectiveness the Company's medical device vigilance system continues to operate in full

comprehensively covering individual adverse event reports group adverse event reports periodic risk evaluation alignment with domestic and international regulatory requirements with the standardization and effectiveness of its

reports key monitoring reports (for innovative products) and product re-evaluations ensuring that adverse events management practices recognized by regulators. In 2025 BGI Biotechnology (Wuhan) Co. Ltd. underwent a routine

and product safety risks of varying types and risk levels are monitored and addressed comprehensively consistently inspection by the Hubei Medical Products Administration receiving zero non-conformities in medical device vigilance

and precisely achieving seamless risk surveillance for marketed products. and adverse event monitoring management fully validating the system's compliance and maturity.

47 48BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Customer service The Customer Service Center fully aligns with ISO 9001 ISO 14001 ISO 45001 ISO 37301 ISO/IEC 27001:2022 ISO/IEC 27701:2019 and ISO 15189 requirements actively pursues certifications and rigorously implements standard

clauses. It enhances service efficiency through quality management builds customer trust via information

BGI Genomics' Customer Service Center is among the earliest established in China's genomics industry. Adhering security and privacy protection standardizes service conduct through compliance management ensures service

to the service philosophy "Empathy and Understanding Catering to Your Needs" it is committed to delivering sustainability with green and safe operations and strengthens professional support with medical laboratory

professional efficient and comprehensive technical support and services positioning customer service as the service standards. By consolidating business relationship data and team assets it continuously optimizes service

core nexus between the Company and its clients. In 2025 the Company continued enhancing its service system processes and customer experience fulfilling the mission "Omics for All" through systematic operations and

upgrading capabilities and optimizing experiences. By consolidating four core assets—business relationships continuous improvement. Below are the certification systems the center has participated in and passed along with

data and team—it solidified customer trust provided essential support for sustainable development and faithfully relevant audit clauses (departments primarily responsible for audits are indicated in red font):

fulfilled its mission "Omics for All."

System name Main clauses involved

Customer service management system 4.2 Understanding the needs and

5.3 Roles responsibilities and authorities

The Company has built a hierarchical dual-track closed-loop collaborative customer service management system. expectations of interested partiesISO 37301 7.3 Awareness

Guided by the top-level vision "Creating Wings for Customer Service" the business layer focuses on iterative 4.5 Compliance obligations 7.4 Communication

refinement of service processes and standards the capability layer emphasizes implementation of intelligent 4.6 Compliance risk assessment

systems and the foundation rests on comprehensive customer service empowerment forming a standardized

service management system covering all scenarios and processes. 4.2 Understanding the needs and

6.1.3 Information security risk treatment

ISO 27001:2022 expectations of interested parties

7.3 Awareness

BGI Genomics' customer service management system 6.1.2 Information security risk assessment

5.2.2 Understanding the needs and

5.4.1.3 Information security risk treatment

ISO 27701:2019 expectations of interested parties

5.5.3 Awareness

Hierarchical progression 5.4.1.2 Information security risk assessment

Deep integration of general and specialized capabilities

5.3 Organizational roles responsibilities and

Creating Business layer authorities 7.4 Communication

wings for Continuous improvement Capability layerIn-depth application and ISO 9001 6.2 Quality objectives and planning to 9.1 Monitoring measurement analysis and customer of operating processes and

service standards practice of intelligent agents achieve them evaluation (9.1.2 Customer satisfaction)

7.3 Awareness

5.3 Organizational roles responsibilities and

Customer All-scenario Customer intent Precise problem Intelligent agent authorities 7.3 Awareness

inquiries responsiveness handoff classification and application and

Data statistics and

analysis ISO 14001handling feedback 6.2 Environmental objectives and planning 7.4 Communication

to achieve them

Customer Research – Planning – Execution – Standardization – Implementation – Supervision –

5 Leadership and worker participation

7.3 Awareness

follow-up Results – Assessment – Incentivization – Continuous Improvement ISO 45001 6.2 OH&S objectives and planning to achieve 7.4 Communication

them

5.3 Laboratory activities (5.3.3 Advisory

Latest

Customer Latest strategies and Latest product Latest laws Latest internal

4.1 Impartiality activities)

service operating organizational and service regulations and contact ISO 15189 4.2 Confidentiality 6.2 Personnel

empowerment procedures structure processes safety standards network 5.6 Risk management 8.5 Actions to address risks and

opportunities

49 50BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

The Company is committed to delivering "accurate professional and reliable" medical and scientific research Customer Satisfaction Survey Management Procedure

services. By establishing standardized service protocols and defining response timeframes across all service

scenarios it has implemented an efficient and robust service response mechanism to effectively address diverse

customer inquiries regarding the testing process.Determining survey Designing and

Service type Specific items Committed processing time Defining survey Defining survey objectives

scope content establishing survey implementing survey

procedures questionnaires

Inquiring about testing progress

registering customer information

updates applying for report mailing 1 business day

and processing donation withdrawal

requests

Consultation Following up on customer intentions

and conducting dissatisfaction follow- 1–2 business days

ups

Donation withdrawal processed Within 5 business days

Follow-up Collection of survey

Data analysis on negative questionnaires and

evaluations quality control of

Accepting complaints 1 business day questionnaire data

Providing complaint progress updates 2 business days

Complaints

Post-resolution customer satisfaction

follow-up 1 business day Formulating Implementing Report writing

service and supervising and conclusion

Investigation and handling of service- improvement plans improvement plans sharing

related complaints 5–10 business days

Others SMS configuration 1 business day

Case study Early colorectal cancer screening: seizing the window for life

Customer Service Capability Improvement In February 2025 the Company launched a shareholder appreciation

initiative offering the Colotect colorectal health test to shareholders

as a demonstration of its commitment to stakeholder well-being

Customer satisfaction enhancement through genomics. Shareholder Mr. Han participated received a test

kit completed sampling and received results indicating positive

The Company has established a 7×24-hour uninterrupted omni-channel customer service system leveraging methylation in three genes. He promptly underwent a colonoscopy

diverse touchpoints such as telephone and online channels to rapidly respond to inquiries comprehensively per medical advice and was diagnosed with intramucosal carcinoma

address customer needs and efficiently resolve issues through closed-loop management—continuously delivering of the sigmoid colon. Thanks to the precise early detection the

professional convenient and trustworthy services. lesion was identified before cancer spread and he made a full

Simultaneously the Customer Service Center has established a regular customer satisfaction survey mechanism recovery post-surgery. Mr. Han later sent a heartfelt thank-you letter

designing tailored questionnaires for different products and conducting periodic surveys and proactive follow- and a commemorative banner sincerely acknowledging the clinical

ups via phone email WeChat and other channels. This enables comprehensive collection of customer feedback value of the Company's product and powerfully validating the real-

on products services and delivery quality which is compiled into dedicated reports to continuously refine service world impact of BGI Genomics' mission: "Omics for All."

quality enhance customer loyalty and long-term retention and support steady business growth. In 2025 agent-level

customer satisfaction remained consistently above 99% maintaining industry-leading service quality.

51 52BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Digital and intelligent service transformation

In 2025 the Company collected 1094 customer satisfaction survey responses achieving a

99% To continuously enhance service quality efficiency and digital intelligence the Company iteratively upgrades satisfaction rate of .

its end-to-end customer service support system. In 2025 it updated its knowledge base with over 10000 entries

solidifying the foundation for expert service delivery. Internally it enhanced the DingTalk app "Medical Encyclopedia"

to enable enterprise-wide knowledge sharing and reuse empowering frontline staff. Externally it upgraded the

intelligent agent "Gene" which—through specialized large-model training and dynamic updates from its proprietary

Customer service quality control management knowledge base—achieved a 70% AI reception rate in 2025 enabling precise detailed and natural interactions

with customers. This steadily advances the deep integration and innovative application of AI in customer service

The Company treats customer service quality as a key performance indicator implementing end-to-end refined continuously optimizing the user experience through technological innovation.control through an intelligent quality assurance system. This includes an AI-powered quality inspection platform

covering phone online and other channels conducting daily proportional checks and re-inspections on every

agent's interactions. Intelligent technologies enhance voice training and standardize service delivery. Real-time

monitoring of agent blind spots regular service philosophy training and sharing of exemplary cases minimize

performance variance. Customer feedback drives a closed-loop process optimization mechanism that rapidly

translates improvements into standardized operating guidelines. Additionally a four-tier quality inspection

workflow—agents inspectors re-inspectors and quality supervisors—ensures closed-loop management from

service record generation sampling re-inspection feedback and coaching training implementation to aggregated

optimization—ultimately enhancing both service efficiency and customer experience.Customer Service Center Quality Inspection Management Process

Agent Quality inspector Re-inspector Quality supervisor Continuous development of a professional customer service team

Drawing on years of operational experience the Company has built a professional stable and highly qualified core

service team with 14 years of deep industry expertise. As of the reporting period end it has served over 4.6 million

Review quality inspection Provide re-inspection

outcomes feedback individuals providing strong talent assurance for high-quality service delivery.Qualification category Number of certified individuals Professional value

Aggregate

Service record Sample for quality Re-inspect quality

and analyze

inspection results inspection results; propose National Senior Health Manager 23 Provide professional health management consultation and

process and guidance to clients

material

optimizations

National Senior Public Nutritionist 14 Provide professional nutrition-related consultation services

Deliver quality inspection

results with guidance

National Senior Customer Service 16 Ensure standardization of service processes and quality control Manager of services

Provide feedback to training lead

for coaching Junior/Intermediate Genetic 24 Provide professional technical services such as genetic Counselor counseling and report interpretation

5354

Key performanceBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

The Company prioritizes building a future-ready talent team. It has formulated the Management Measures for Public Customer complaint handling process

Customer Service Training in the Customer Service Center and the Competency Verification Plan for Long-term

Employees. Regular systematic training and assessments are conducted to continuously enhance the professional

competence of the customer service team fully empowering them to meet diverse role requirements. The Company Process node Core work requirements Committed time limit

formulates a detailed annual training plan at the beginning of each year conducts year-end competency verification

and makes monthly adjustments based on actual conditions to ensure customer service personnel comprehensively Complaint Receive customer complaints through all channels

master product knowledge communication skills and system operations thereby delivering high-quality and acceptance and complete complaint assessment and classification and

transfer transfer to the corresponding responsible department

1 business day

efficient services to customers. and personnel

Case Conducting customer service training and competency verification to solidify the

study foundation of service professionalization Process Synchronize phased complaint handling progress with Complete the first progress feedback

feedback the customer and promptly communicate the handling status within 2 business daysIn 2025 the Company organized specialized training

competency verification and on-site assessments

focused on enhancing customer service capabilities. By Investigation For different complaint types such as service-related Complete investigation and handling of

integrating centralized lectures directive rollouts and and handling and quality-related conduct special investigations event service-related complaints within 5–10 grading and formulate and implement resolution plans business days

practical evaluations it strengthened customer service

personnel's understanding and application of business

processes service standards and communication Follow-up after

After complaint resolution complete a customer

resolution satisfaction follow-up to confirm the customer's 1 business day

requirements promoting the translation of training acceptance of the outcome

outcomes into on-the-job performance and further

solidifying the professional capabilities and service

Closed-loop Conduct root cause analysis of the complaint drive Continuous follow-up to achieve

quality foundation of the customer service team. The Company organizes on-site customer service training and optimization relevant departments to implement corrective actions systematic optimization

competency assessment and verification and track the effectiveness of improvements

In 2025 the Company conducted 7 customer service training sessions covering 100% of its

customer service personnel. In 2025 the Company received 35 customer complaints amounting to 1 complaint per RMB 100

million in revenue.The customer complaint resolution rate was 100%.Customer complaint handling

The Company has formulated the Management

Regulations for Handling Medical Customer

Complaints clarifying standards and time limits for Responsible marketing

the entire complaint handling process to ensure

customer concerns are addressed promptly in a BGI Genomics strictly complies with relevant laws and regulations including the Advertising Law of the People's

standardized manner and through a closed-loop Republic of China the Anti-Unfair Competition Law of the People's Republic of China and the Law of the People's

process. The core process is as follows: Republic of China on the Protection of Consumer Rights and Interests. The Company rigorously adheres to regulatory

red lines to ensure all marketing activities are conducted within the legal framework. It deeply integrates the concept

of responsible marketing into its entire business operations establishing a comprehensive end-to-end marketing

compliance management system. Marketing practices are strictly regulated to resolutely eliminate violations such

as false advertising and unfair competition fully committed to fostering a fair transparent and trustworthy market

environment safeguarding consumers' legitimate rights and interests and promoting the healthy and orderly

development of the genomics and health industry.

5556

Key performance

Key performanceBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Routine closed-loop management of marketing activities

The Company has established a routine full-process control mechanism of "pre-review in-process monitoring and

post-review" to implement full-lifecycle closed-loop management of marketing activities and comprehensively mitigate

marketing compliance risks. In terms of building the science communication content system

Pre-review Centered on its core business areas—including reproductive health cancer prevention and control

The Company has established a stringent multi-tiered marketing content review system stipulating that all externally infectious disease prevention and control and chronic disease management—the Company has

released marketing information promotional materials and advertising content must undergo a dual-review process: developed a professional rigorous and accessible science communication content system. This

preliminary review by the business department followed by specialized review by the compliance and legal departments. system covers multiple dimensions such as disease prevention knowledge principles of genomic

The focus is on verifying the authenticity scientific validity and compliance of promotional content. Exaggerated claims technology product application scenarios and test result interpretation ensuring all content

false advertising absolute language or distorted facts are strictly prohibited ensuring all external marketing information is backed by authoritative scientific research and clinical data and avoiding any exaggerated or

is supported by authoritative scientific evidence. No content may be published externally without passing this review.misleading statements.In-process monitoring

The Company conducts routine dynamic monitoring of published marketing content and ongoing campaigns In terms of science communication channels and formats

establishing an omni-channel marketing behavior monitoring mechanism covering online new media platforms offline

promotional events academic engagements and channel partnerships. This enables timely identification and handling

of non-compliant promotional activities swiftly containing risk propagation. Simultaneously the Company strictly abides Online the Company leverages new media channels such as its official WeChat Official Account

by laws and regulations governing market competition prohibiting unfair practices such as improper benefit transfers video channels and live streaming platforms to continuously publish popular science articles

commercial bribery or undue promises. It also prohibits suppliers from seeking procurement advantages or monopolistic expert interview videos and short science videos creating a series of science communication IPs to

positions through improper means like benefit transfers or special returns fully committed to maintaining a fair and provide the public with convenient and accessible health knowledge services. It has also launched

orderly market competition environment. the ChatGeneT professional genomics consulting platform which offers the public knowledge

on genetic diseases genetics education and personalized health advice based on a professional

Post-review knowledge base lowering the cognitive barrier to understanding genomic technologies and related

The Company has established a marketing compliance risk review and rectification mechanism. For compliance issues products.and potential risks identified in marketing activities it conducts root cause analysis to identify underlying problems Offline in conjunction with health-themed days such as National Ear Care Day World Thalassemia

and assign rectification responsibilities formulates targeted optimization measures and concurrently updates review Day Cancer Prevention and Control Promotion Week and World Gut Health Day the Company

standards and control requirements to establish a closed-loop management system continuously refining the marketing collaborates with local health commissions medical institutions and public welfare organizations

compliance management framework. to conduct free clinics health lectures grassroots science outreach tours and public welfare

Conduct regular responsible marketing training screenings. These activities reach deep into communities and primary healthcare institutions providing face-to-face explanations of genomic health knowledge and the value of its products

The Company incorporates responsible marketing and compliance communication training into its company-wide and services. Simultaneously through academic marketing activities it engages in professional

training system conducting regular tiered specialized training for marketing-related personnel to continuously strengthen academic exchanges and product knowledge dissemination with clinical experts to enhance

enterprise-wide compliance awareness and the philosophy of responsible marketing solidifying the ideological scientific understanding of its products within the professional community and promote the delivery

foundation for marketing compliance. Adopting a blended online-offline training approach it achieves full coverage of

personnel across the entire marketing chain including the Customer Service Center and Marketing Center. Compliance of standardized scientific health knowledge.marketing training is also included as a mandatory component of new employee onboarding ensuring new hires are

familiar with marketing compliance red lines and policy requirements from day one and can only commence work after Others

passing relevant assessments.Deepening product and service popularization education Throughout the entire product promotion and customer service journey the Company has

The Company consistently adheres to the principle of "science popularization first scientific empowerment" integrating established a full-cycle consulting service system with professionals providing one-on-one product

product and service popularization education throughout the marketing process. It delivers multi-format multi-channel explanations report interpretations and health advice before during and after testing. This ensures

genomics and health knowledge dissemination to customers and the public helping them scientifically understand the customers gain a comprehensive and accurate understanding of relevant product and service

principles applicable scope value and limitations of the Company's products and services. This breaks down cognitive information enabling them to make informed consumption decisions truly empowering marketing

barriers eliminates misleading promotions and effectively safeguards consumers' right to be informed and their right to through science communication and safeguarding public health with a sense of responsibility.choose.

57 58BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Innovation-driven development Major R&D

project name Project purpose Project progress Intended goals

R&D and innovation

Domestic Completed replacement testing Achieve domestic substitution of

The Company continues to deepen the standardization of its R&D system focusing on full lifecycle management substitution of all imported raw materials major raw materials while ensuring for the NIFTY Achieve domestic production of product testing performance and

of R&D center projects. It has unified and standardized management requirements across the entire chain— non-invasive all raw materials for the reagent in the NIFTY reagent kit with

prenatal testing kit domestic reagents and initiated

stability significantly reducing

including project initiation execution process monitoring tech transfer and project closure—to vigorously testing costs and improving the

(NIPT) product the registration for raw material stability and controllability of raw

advance the transformation and full-cycle management of R&D outcomes. The Company strictly implements the reagent kit changes material supply

R&D Center Project Management Methodology to ensure R&D outputs are highly aligned with the Company's

strategic development needs project progress meets design objectives and R&D cost control satisfies accounting

requirements driving the comprehensive standardized scientific and efficient implementation of R&D

Develop carrier screening Completed the development Establish a "Five-pre" product

management. Development prenatal screening newborn of localized products for system based on the WGS

of "Five-pre" screening preimplantation carrier screening and newborn technology platform to provide a R&D and innovation management structure products based genetic testing (PGT) and other screening based on the one-stop comprehensive high-WGS technology platform level solution for the entire birth

Based on the actual operational effectiveness of its R&D management system the Company continuously reviews on the WGS technologies based on the WGS technology platform completing a full- and released localized WGS defect prevention and control

and optimizes its R&D management regulations and systems establishing a research management organizational platform line upgrade of the "Five-pre" testing solutions based on the system covering preconception

products MGISEQ-2000 and DNBSEQ-T7 prenatal preimplantation and structure with clear divisions of labor and well-defined responsibilities and authorities constantly strengthening the platforms preschool stages

foundational bedrock for the Company's innovation capabilities.Advance modular and

Head of the R&D center Discipline leader containerized R&D for WGS Promote standardized database Build a modular and pluggable WGS bioinformatics analysis platform

Oversee the overall strategic direction of Participate in the approval and R&D of a bioinformatics data analysis R&D based on standard modular

the R&D center and be responsible for decision-making for core stages modular and to enable rapid iteration and processes achieve standardized

that supports rapid iteration and

hot updates of clinical-grade

the holistic resource coordination and of R&D projects such as initiation containerized agile global deployment of WGS iterative management of WGS bioinformatics products; simultaneously improve products and diversified process analysis pipelines; develop a allocation of the R&D system. change tech transfer and closure. analysis analysis speed and reduce interfaces and rapidly deploy multi-modal deployment solution

platform for computing and storage costs express WGS carrier screening covering on-premises servers

R&D team WGS facilitating the comprehensive WGS and newborn screening private clouds and public clouds

of the R&D promotion and accessible WGS to meet compliance requirements

center application of WGS technology across different global regionsProject management position PBU leader

Does not directly participate in frontline Lead the entire R&D process for

R&D work. The core responsibility is to PBU projects and assume full

assist the project team in achieving R&D responsibility for execution and Continuously expand the detection

goals provide professional support for outcomes throughout the project's scope optimize detection

the entire project execution process lifecycle. performance and improve the

and conduct tracking monitoring and

control of project execution. Optimization Optimize the molecular diagnostic Deploy express testing for WGS

detection rate of monogenic

PBU members and upgrade of products and release a localized

disease testing products through

WES and WGS product portfolio and improve the express WGS solution based on iterative experimental technologies

Collaborate to complete various R&D products overall detection rate the DNBSEQ-T1+ sequencer and optimization of proprietary

execution tasks according to project analysis algorithms; enhance the

R&D needs and division of labor. functionality of the cloud-based

interpretation platform to support

product localization

Major R&D projects during the reporting period

BGI Genomics adheres to an innovation-driven strategy focusing on key technological breakthroughs and modular Optimization

and upgrade Develop single-molecule Release single-molecule

Achieve more comprehensive

upgrades of its sequencing platforms. By strengthening the domestic sourcing of core raw materials and enhancing of thalassemia thalassemia testing products thalassemia gene testing and

bioinformatics analysis efficiency the Company not only solidifies its foundation of technological self-reliance but gene testing thalassemia testing products and localized solutions product iteration through single-molecule sequencing technology.also continuously optimizes its product portfolio effectively supporting sustainable business growth and global products

expansion.

59 60BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

R&D and innovation achievements Case Launching the ChatBGI intelligent assistant to enhance the accessibility of precision

The Company actively leads or participates in the development of standards at all levels in fields such as reproductive study health services

health cancer prevention and control infection prevention and control and multi-omics big data. As of the end of the

reporting period the Company has cumulatively led or participated in the development of 121 standards including In February 2025 BGI Genomics Internet Hospital

1 international standard 2 "Belt and Road" regional standards 17 national standards and 60 group standards. The officially launched ChatBGI providing users with

issuance and implementation of these standards have further standardized the clinical application scenarios of genetic 24/7 intelligent services including genetic testing

testing technologies and provided critical support for the quality control of related products and services. Meanwhile the consultation product inquiries report interpretation

Company is deeply involved in the establishment of numerous domestic and international industry standard organizations and health management advice covering scenarios such

and industrial alliances playing a significant role in promoting the formulation and implementation of globally leading as reproductive health cancer prevention and control

standards and contributing to the high-quality development of the industry. chronic disease management and infection prevention

and control.In the field of deep integration between artificial intelligence and precision medicine BGI Genomics continues to deepen

external collaborations and achievement transformation. The Company has established partnerships with leading Leveraging the synergistic capabilities of a professional

institutions including Peking Union Medical College Hospital the National Clinical Research Center for Laboratory knowledge base and large language models this platform

Medicine at the First Affiliated Hospital of China Medical University the Obstetrics & Gynecology Hospital of Fudan has enhanced service response efficiency and user

University PengCheng Laboratory and Zhejiang Lab focusing on joint research in areas such as large models for rare experience providing support for the implementation BGI Genomics Internet Hospital launches ChatBGI intelligent

diseases AI demonstration bases multimodal models bioinformatics computing compression and intelligent Agent R&D. of "AI + testing services" and the democratization of health management assistant

The Company's related AI solutions have received multiple industry recognitions and its patent and software copyright precision health management.portfolio are steadily expanding.Hospital and scientific research cooperation Case Exhibited at international technology fairs showcasing innovative capabilities in study localized AI-powered testing

In June 2025 BGI Genomics participated in the 11th China (Shanghai) International Technology Import & Export

Fair (CSITF) showcasing the "SIRO High-throughput Gene Testing Localized Medical Solution" and presenting it

as a representative achievement at the CSITF press conference. This platform integrates standardized laboratory

workflows AI-powered intelligent analysis and localized deployment achieving a closed-loop "sample-in report-

out" process. It demonstrates the Company's technological prowess in intelligent testing for precision medicine

Engage in in-depth collaboration with

Peking Union Medical College on large Jointly apply with the National Clinical Collaborate with the Obstetrics Cooperate with PengCheng and provides a new pathway for bringing gene testing to grassroots levels and enhancing the accessibility of clinical

models for rare diseases including Research Center for Laboratory & Gynecology Hospital of Fudan Laboratory in fields such as

co-authored publications and joint Medicine at the First Affiliated Hospital University in Shanghai to apply bioinformatics computing

applications for clinical and translational of China Medical University to establish for the Shanghai Scientific services.projects and present findings at the 2nd an artificial intelligence demonstration Intelligence Reserve Project with

compression and life science

large models; cooperate with

Annual Conference on Rare Diseases of the base in-depth cooperation on prenatal Zhejiang Lab on Agent R&D

Chinese Medical Association multimodal large models

Hospital and scientific research cooperation

The intelligent integrated gene testing

iGeneT Pro was recognized as the "Annual solution for precision medicine won 6 core patents accepted

Sci-tech Innovation Practice Case" at the third prize in the Health Big Data iGeneT Pro won the BGI Genomics 3 software copyrights

2024 Southern Weekly Sci-tech Innovation Application Technology Track of 2024 Huabiao Award registered and multiple patent

Conference the Xiong'an Medical and Health applications pending

Technology Application Competition

BGI Genomics showcases SIRO high-throughput gene testing localized medical solution at CSITF

61 62BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Case Host the International Conference on Genomics building consensus on innovation in Case study Specialized training on trademark protection

study omics and AI

In October 2025 the 20th International Conference on Genomics (ICG-20) was held in Hangzhou gathering over 100 To comprehensively enhance the Company's professional capabilities in trademark application and protection

experts and scholars from 19 countries and regions for in-depth discussions on "The Future of Omics and AI." During and mitigate brand risks in business operations the Intellectual Property Department held a "Specialized Training

the conference BGI Research and Zhejiang Lab jointly launched Genos the world's first universal foundational on Trademark Protection" in April 2025. The training covered fundamental trademark knowledge registration

model for the human genome with tens of billions of parameters. This showcased the Company's cutting-edge application procedures examination criteria as well as practical matters such as trademark usage guidelines and

exploration at the intersection of omics and artificial intelligence and injected new momentum into global scientific evidence collection aiming to empower the development of new quality productive forces through high-quality and

collaboration and the innovative development of precision medicine and life sciences. efficient IP protection.The 20th International Conference on Genomics The specialized training on trademark protection

In 2025 R&D investment amounted to RMB 508 million. In 2025 a cumulative total of 802 patents were held.R&D investment accounted for 13.71% of operating revenue. A cumulative total of 919 software copyrights were held.A cumulative total of 1084 trademarks were held.Intellectual property protection

BGI Genomics adheres to institutional development as a key driver to promote the standardization and normalization 104 new patent applications were filed.of its intellectual property (IP) management. The Company has formulated and continuously refined internal

regulations including the IP Transfer Management Measures Patent Management Measures IP Reward Measures 55 new patents were granted.Trademark Management Measures and Technical Secrets Management Measures forming a hierarchical and well-

integrated institutional system. Concurrently the Company has established an Intellectual Property Department

as a first-level unit directly overseen by the General Manager to ensure the deep integration of the IP strategy with 43 new software copyrights were registered.the Company's overall business objectives achieving seamless alignment from top-level design to on-the-ground

execution.

6364

Key performance

Key performanceBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Ethics of science and technology Building a culture of ethics of science and technology and social participation

BGI Genomics has always been guided by its corporate vision of "Omics for All." Deeply aware of the symbiotic The Company actively promotes the building of a culture of science ethics primarily through training and social

relationship between technological advancement and ethical governance the Company adheres to the principle of engagement. By conducting regular training on the ethics of science and technology it enhances employees' ethical

"responsible innovation" and upholds bioethics and the ethics of science and technology as its core values. While awareness and compliance capabilities ensuring that research and business activities adhere to ethical norms and legal

advancing scientific and technological progress the Company is committed to fully protecting participant rights requirements. Simultaneously BGI Genomics emphasizes social engagement proactively communicating with regulatory

safeguarding personal privacy and upholding social fairness and justice thereby achieving a harmonious unity bodies research institutions and the public sharing practical experience in science ethics and participating in industry

between technological development and ethical constraints. standard setting and research projects to foster ethical consensus and social responsibility in the life sciences field.Vision Uphold the core philosophy of "Omics for All" and make "tech for good" the starting point for all innovation Case study Symposium on "Intelligence Leading the Future Ethics Walking Alongside"

In April 2025 the BGI Science and Technology Ethics Committee held its annual meeting and the symposium on

Ethical Adhere to "responsible innovation" and uphold bioethics and the ethics of science and

principles technology as core values "Intelligence Leading the Future Ethics Walking Alongside" focusing on ethical governance in the integration of AI and

biotechnology. Experts from universities research institutes and medical institutions discussed frontier topics such

as algorithmic bias data privacy and human-machine collaborative responsibility analyzing the balance between

Development While advancing scientific and technological progress protect participant rights technological advancement and ethical constraints from an interdisciplinary perspective. The meeting reached multiple

goals safeguard personal privacy and uphold social fairness and justice consensus points including improving review standards establishing risk early-warning mechanisms and strengthening

ethics training. This reflects BGI Genomics' commitment to integrating ethical considerations into technological

Management system and structure for the ethics of science and technology innovation leveraging an open platform to gather collective wisdom and providing practical approaches for the responsible development of emerging technologies demonstrating the Company's leadership and social responsibility in

BGI Genomics has established an ethics management structure centered on the Science and Technology Ethics the field of science and technology ethics.Committee and the Compliance Department and has formulated institutional documents such as the Bioethics

Management Measures and Ethics Management Regulations. The Company's Science and Technology Ethics Committee is

responsible for conducting ethical reviews risk assessments and compliance consultations. Its members include experts

from fields such as ethics law and medicine ensuring the professionalism impartiality and independence of the ethical

review process. Meanwhile the Compliance Department oversees key areas including life science ethics data security

and human genetic resources management. It formulates relevant norms and regulations conducts risk assessments

compliance training and supervision and inspection to ensure the compliant development of all Company operations.BGI Genomics' management mechanism for the ethics of science and technology

Ethics training and consultation

The Science and Technology Ethics Committee provides ethics training courses for BGI employees and

accepts daily ethical consultations to help BGI employees enhance their awareness of the ethics of science

and technology

Daily management mechanism

Establish a graded and classified project management system and implement an ethical risk assessment

mechanism

Collaborative compliance management

The Science and Technology Ethics Committee collaborates with multiple departments including the

Compliance Department R&D management and Legal Affairs to conduct joint oversight effectively

preventing and promptly addressing potential ethical risks

65 66BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Data security and customer privacy 14 of BGI Genomics' key business systems have passed the Level III assessment and certification under China's

Classified Protection of Cybersecurity framework

BGI Genomics strictly complies with relevant laws and regulations including the Cybersecurity Law of the People's

Republic of China the Data Security Law of the People's Republic of China and the Personal Information Protection Cybersecurity

Law of the People's Republic of China . Adhering to the principle of coordinating development and security the classified

protection Name of assessed system

Company consistently treats data security and customer privacy protection as a critical foundation for ensuring assessment level

business continuity safeguarding customer rights reinforcing cooperative trust and supporting digital transformation.It promotes the establishment of a secure controllable standardized transparent and clearly accountable data ChatGeneT Genetic Counseling Assistance System iGeneT End-to-End Gene Interpretation

governance system providing robust support for the stable operation and long-term value creation of its precision Platform BGI Zhihui Health Management

medicine business. System Unified ID System Whale Cloud Report System PETA System Birth Defect Prevention

Governance Level III and Control System HALOS All-in-One Gene Sequencing System Government Public

Livelihood Testing Project Information System

BGI Genomics has formulated internal policies and systems including the Implementing Rules for Data Security BGI Genomics Medical Mall Cloud-based Public

Management Management Measures for Data Security Classification and Grading Management Measures for Livelihood Platform BGI Cancer Early Screening BGI Genomics certified with ISO/IEC 27001 System BGI Medical Testing Platform

Privacy Policies and Specifications for Personal Privacy Data Processing. The Company continuously enhances its Information Security Management System

data security governance system covering the full chain of decision-making supervision execution and business

usage. Data protection requirements are embedded into all aspects of business development R&D innovation

delivery operations and external collaboration driving the shift of data security from passive defense to proactive

governance. This provides foundational support for the Company's stable operations technological innovation and Strategy

compliant development. In 2025 the Company obtained ISO/IEC 27001 Information Security Management System

certification and implemented the ISO/IEC 27701 Privacy Information Management System for the first time ensuring BGI Genomics incorporates data security as a critical enabler of its digital operations and compliance management.standardized management of data security and customer privacy. The Company continuously assesses the impact of data processing activities on business continuity customer

trust and long-term development from a risk prevention and control perspective. It advances security governance

BGI Genomics' governance structure for data security and customer privacy protection capability building in synergy with digital business expansion extending data management from basic compliance

assurance toward enhanced operational resilience and value creation support.BGI Genomics' identification and response to risks and opportunities related to data security and

Data Security and Personal Information customer privacy

Decision-making level Protection Committee

Data Committee Office Risk/Opportunity Specific description Impact duration Financial impact Response strategy

Management and Compliance Legal Quality Management Risk

supervision level Department Department Department

The Company handles

Human Genetic Resources important data genetic Strengthen data asset

Execution level Administration Office Information Security identification data Increased investment inventory management

(Ministry of Science and Management Department Compliance risk and sensitive personal in compliance and implement

Technology) (classification grading information. Inadequate Medium- and remediation; potential classification grading

and management of data asset inventory long-term rise in penalties audit highest-standard

important data) classification grading or and legal response adherence and

differentiated protection costs. tiered protection

IT DeIpTar部tment Interna内l A审ud内it a控nd部 Internal Process and IT may lead to compliance requirements.Control Department 流程De与pa信rtm息en化t 部 breaches and liability risks.Other

participating levels Supply Chain Department Human Resources Department ......

67 68BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Indicators and targets

Risk/Opportunity Specific description Impact duration Financial impact Response strategy

BGI Genomics places high importance on data security and customer privacy protection consistently treating it as

Implement principles a vital foundation for ensuring stable operations maintaining customer trust and supporting sustainable business Risks such as leakage

Operational tampering unauthorized Business interruption of minimum necessity development. The Company adheres to the principle of balancing compliance management with business growth

risks (collection access and use beyond Short and losses; increased

permission control

secure transmission continuously enhancing its data governance capabilities and privacy protection standards and is committed to transmission use authorized scope exist medium term costs for customer log retention data building a secure standardized and trustworthy data management environment.and permission in data collection compensation and

management) transmission use and trust restoration. desensitization

export. and approval-based authorization. Key performance

Opportunities Indicator Unit 2025 data

Number of incidents related to data security and customer privacy breaches Cases 0

Monetary value involved in incidents of data security and customer privacy breaches RMB 0

Continuously improving

systems certifications Reduced losses from Continuously advance

Customer information security and privacy protection training conducted Sessions 8

Opportunities training and red-blue major incidents; system optimization for governance team exercises enhances Medium- and certification Participation in customer information security and privacy protection training Person-times 552

maturity and trust governance maturity long-term enhanced partnership

enhancement customer trust and stability and brand

maintenance training

trust. and drills and security

Information security emergency drills conducted Sessions 2

digital business support culture building.capabilities. Participation in information security emergency drills Person-times 500

Full life-cycle data security management

The Company is advancing BGI Genomics implements full life-cycle data security management with data classification and grading as the

OmicsDB a unified data Expanded revenue Continuously cornerstone. The Company establishes baseline rules for differentiated protection based on data attributes business security management from data products promote platform- purposes affected subjects and impact severity. Limited security resources are prioritized for high-sensitivity high-platform and a data asset

Opportunities for management system improved operational based management impact scenarios to align management requirements with protection intensity thereby enhancing the precision of

data assetization and to transform data from Medium- and efficiency of standardized long-term data assets and accumulation data governance and the efficiency of resource allocation.productization a resource into assets

products and services and strengthened growth compliant data

has begun exploring data drivers for new circulation and data businesses. product development. BGI Genomics' closed-loop management for full life-cycle data securityproduct commercialization

and value realization.Collection stage Transmission stage

Clearly define the purpose scope method and legal Utilize secure transmission channels encryption

basis of data collection implementing transparency integrity verification and access control to prevent

and the principle of minimum necessity. data leakage during transmission.Impact risk and opportunity management

BGI Genomics has established a closed-loop management system for impacts risks and opportunities centered on Deletion and destruction stage Use and sharing stage Storage stage

"pre-event identification and assessment – in-event tiered control – post-event emergency response – continuous Promptly delete anonymize or Data must be used strictly within Implement encryption

optimization and improvement." The Company embeds data security and personal information protection destroy data that has fulfilled its the authorized scope validity desensitization access control

processing purpose or reached period and purpose. Export of backup and recovery and

requirements into key scenarios including scientific research testing delivery system development and cross- its storage period ensuring the highly sensitive data is generally storage period management in

border collaboration. While mitigating risks such as data leakage non-compliant cross-border transfers and system entire process is traceable and restricted and any use beyond alignment with classification

anomalies it continuously strengthens the compliance support capabilities operational resilience and value auditable. the original purpose requires re- strategies.approval.conversion foundation of its digital business.

69 70BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Cross-border data transfer management BGI Genomics' specialized control measures for genetic data security

BGI Genomics regards cross-border data transfer management as a critical boundary control measure for aligning Define key scope

domestic compliance requirements with global business collaboration. Centered on compliance review tiered filing Include human genetic resources information raw gene sequencing data and genetic

and prudent approval the Company has established a cross-border data transfer control mechanism strengthening identification data as key protected data categories.identification and process management for outbound transfers of personal information important data and gene-

related data. This ensures cross-border business operations are conducted lawfully transparently and controllably

and that all cross-border data transfers comply with applicable laws and regulations. Strengthen collection compliance

BGI Genomics' control measures for cross-border data transfer Implement informed consent legal source verification and written authorization requirements to

standardize pre-collection management of genetic data.Implement approved delivery

Outbound data identification Tiered filing Implement tiered review for R&D scientific research and customer request scenarios with

responsibilities shared among the business department Human Genetic Resources Administration

Office Data Committee IT Department and Delivery Center.Clearly identify outbound data Implement filing approval or

subjects—including personal escalated decision-making for cross-

information important data genetic border data transfer scenarios of Strictly control the boundaries of use

identification data and human genetic varying scale and type. Data use is limited to the approved purpose and scope; transfer to third parties or changes in use

resources information—and enforce

the principle of "whoever transfers without authorization are prohibited.declares and is responsible."

Strictly adhere to the red line for cross-border transfer

Implement filing approval and specialized review requirements for cross-border transfer

of genetic data; for cases involving human genetic resources information follow prescribed

supervisory approval procedures

Specialized review Record review

Data security emergency management

Individual cases with unidentifiable risks Continuously verify outbound data

are submitted to the Data Committee content against actual transmissions In accordance with the Emergency Plan for Data Security Incidents BGI Genomics continuously refines its data

for approval; cases involving human through filing forms approval forms security incident response system treating emergency management as essential support for business continuity

genetic resources information undergo monthly reports and annual reviews.specialized approval procedures as customer privacy rights protection and compliance baseline integrity. Through proactive planning unified response

required by regulations. protocols and coordinated incident handling mechanisms the Company extends data security management from

routine protection to resilience capacity building enhancing rapid response resource mobilization and impact

containment capabilities during emergencies. This minimizes adverse effects on operations brand reputation and

stakeholder trust providing assurance for the steady development of its digital business.Specialized control for genetic data security

Privacy protection management

BGI Genomics designates genetic data security as a priority area within its data governance framework implementing

specialized management for highly sensitive and high-impact data such as human genetic resources information raw

BGI Genomics integrates privacy protection throughout information system development business process design

gene sequencing data and genetic identification data. The Company strengthens lawful collection classification and

and personal information processing activities. Focusing on compliant notification minimum necessity explicit

grading approved delivery usage constraints and cross-border transfer controls establishing a dedicated genetic data

consent data desensitization and anonymization the Company continuously improves its personal information

security control mechanism. It enhances human genetic resources management and ensures genetic data protection

protection mechanisms to balance legitimate data utilization with privacy rights safeguards thereby strengthening

requirements are integrated across key scenarios—including scientific collaboration product R&D testing delivery and

stakeholders' trust in its data governance capabilities.cross-border cooperation—continuously solidifying the compliance and trust foundations for its precision medicine

business.

71 72BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Case Conduct red-blue team exercises to enhance practical data security protection

study capabilities Supply chain management system and regulations

In November 2025 BGI Genomics organized a two-week professional red-blue team cyber exercise simulating Guided by the management principles of "standardization efficiency collaboration and controllability" BGI

real-world attack scenarios in a controlled environment to systematically test critical areas including identity Genomics has formulated institutional documents including the Procurement Management System Supplier

authentication access control network segmentation and supply chain security identifying and exposing potential Management System Supply Chain Bidding and Procurement Management System and Engineering Project

vulnerabilities. The exercise directly drove the implementation of security enhancements such as unified identity Procurement Management Measures. Through cross-departmental collaboration and SRM system implementation

authentication multi-factor authentication and network zoning further improving the specificity operability and the Company has evolved supply chain management from transactional procurement to a full-process governance

cross-team coordination of emergency response plans and continuously strengthening the Company's overall system encompassing demand initiation sourcing and pricing contract signing order execution and performance

cybersecurity posture. review continuously enhancing supply chain resilience and management precision.Case Conduct data security training to solidify the privacy protection line of defense across BGI Genomics' supply chain management governance structure

study the industry chain

Supply Chain Department

In 2025 BGI Genomics held 8 specialized data security

training sessions with approximately 542 participants and Coordinates supply chain procurement supplier management and performance

about 10 hours of instruction. The sessions provided in-depth execution serving as the core management unit for the supply chain.coverage of medical business compliance data security and

customer privacy protection systematically explaining data Business Execution Unit

classification and grading personal and sensitive information Sourcing Group

protection full life-cycle security management and legal

responsibilities reinforced by case studies to strengthen risk Responsible for category strategy formulation procurement sourcing supplier development and admission initiation and organizing on-site factory visits sample

awareness and protective measures. The training enhanced validation technical compatibility assessments and pricing process advancement.the compliance and privacy protection capabilities of

employees and partners jointly fortifying the supply chain's Demand Management Group

data security defenses and fostering a secure trustworthy Order Management Group: Responsible for order creation delivery tracking

collaboration environment. coordination of goods receipt and payment milestones handling returns exchanges

On-site data security training and replenishments and recording delivery and quality deviations in supplier performance.Supplier Management Group

Responsible for supplier qualification review admission assessment daily monitoring

Supply chain management performance evaluation suspension and exit file maintenance and risk monitoring; serves as the lead unit for supplier full life-cycle management.BGI Genomics adheres to the supply chain management philosophy of "collaborative win-win and sustainable

Collaborative Support Unit

development" strictly complying with relevant laws and regulations such as the Bidding Law of the People's

Republic of China. The Company has built a comprehensive supply chain management system and continuously Legal Affairs Department: Responsible for legal risk review and approval of contract

advances the standardization of the end-to-end process—including procurement sourcing bidding execution and agreement clauses.supplier admission performance evaluation exit management and file updates. Quality efficiency compliance risk Finance Department: Responsible for providing input on commercial terms

control and collaborative win-win principles are integrated across all supply chain activities promoting synergistic processing payment requests and supporting payment approvals.development and steadily enhancing supply stability business continuity and procurement transparency thereby Requesting Department: As the originator and user of procurement needs

laying a solid foundation for the Company's high-quality development. participates in supplier quality evaluation and provides feedback on performance

issues.Internal Audit and Internal Control Department: Responsible for monitoring process

execution investigating violations and recommending blacklisting.

73 74BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Supplier ESG evaluation admission and due diligence Supplier dynamic assessment and exit mechanism

BGI Genomics treats supplier ESG evaluation admission and due diligence as a key lever to enhance supply chain

quality resilience and responsible governance continuously embedding sustainability requirements at the outset of Daily monitoring Semi-annual performance Graded and classified

partnerships.Collect transaction data in real time via Conduct performance reviews Classify suppliers into five tiers

the SRM system to track performance every six months scoring (S A B C D) based on scoring

of all suppliers; conduct focused across five dimensions: quality results distinguishing excellent

BGI Genomics' supplier ESG evaluation admission and due diligence mechanism monitoring of core suppliers and key delivery cost service and good qualified emergency material suppliers accounting for the technology. backup and non-conforming

top 80% of procurement spend. suppliers.Classified admission management Basic qualification review

Implement differentiated admission Conduct preliminary reviews focusing on

criteria based on procurement legal entity status operational compliance Rectification and guidance Suspension and exit Rectification and guidance

scenarios collaboration frequency supply capability and performance

and procurement value to enhance the fundamentals to establish a robust Issue improvement requirements via For suppliers with no transactions for Issue improvement

relevance and standardization of supplier cooperation entry threshold. email or phone to emergency backup two consecutive years unsatisfactory requirements via email or

management. and non-conforming suppliers performance major incidents or legal/ phone to emergency backup

conducting on-site reviews when financial/audit/compliance risks initiate and non-conforming suppliers

necessary. suspension review exit or reinstatement conducting on-site reviews when

per established procedures. necessary.Rectification review and closure Embedding ESG requirements

Supplier ESG assessment management

Implement rectification Incorporate environmental

tracking and verification responsibility labor

for identified issues and human rights and BGI Genomics embeds green development requirements throughout procurement and collaboration management

ensuring effective linkage business ethics into establishing a green procurement system and prioritizing environmentally friendly materials and equipment.among admission review supplier evaluation and

issue remediation and contractual obligations Through environmental admission reviews environmental clauses in contracts socio-environmental impact

continuous improvement. extending responsibility assessments and environmental responsibility commitments from partners the Company ensures procurement

requirements to the front

end of procurement. activities balance business needs with environmental impact control promoting the integration of resource

conservation environmental friendliness and supply chain sustainability.BGI Genomics' supply chain ESG assessment management mechanism

Key on-site due diligence Technical and quality verification

Admission-

Organize cross-departmental on-site Ensure stable product quality technical Before new suppliers are added to the supplier database they undergo comprehensive evaluation on side

reviews for core materials and key compatibility and delivery feasibility quality environment cost delivery and service. embedding

suppliers to comprehensively verify through sample testing pilot trials and

production capacity assurance quality trial production validation. Contractual Require suppliers in procurement contracts to comply with applicable environmental regulations and

control and service capabilities. constraints explicitly prohibit supplied products from causing environmental pollution.Supplier evaluation assessment and exit Identify supply chain environmental risks and improvement opportunities through social and

Assessment-side

environmental impact assessments. implementation

BGI Genomics extends supplier management from "static admission" to a closed-loop mechanism encompassing Cooperation-

side Integrate environmental responsibility with daily supplier management to strengthen partners'

"continuous monitoring semi-annual review classified rectification suspension and exit and file maintenance." guidance environmental risk identification and self-management.Through hierarchical and tiered management it strengthens supply risk early warning and performance correction

ensures security of core material supply improves the overall quality and traceability of the supplier base and Promote sustained implementation of green requirements through framework agreements standard/ Management-

non-standard contracts and annual contract maintenance mechanisms. side support

shifts supply chain management from reactive handling to proactive prevention and continuous optimization. The

Company rigorously selects high-quality suppliers to ensure a stable and reliable supply chain.

75 76BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Supplier communication and cooperation Industry collaboration

BGI Genomics views supplier communication and cooperation as a key driver for enhancing supply chain stability BGI Genomics is committed to promoting high-quality industry development through open collaboration

advancing technological progress and strengthening quality assurance. Through mechanisms such as technical consistently treating sectoral cooperation as a key enabler for deepening technological innovation accelerating

exchanges framework collaborations joint reviews on-site visits and rectification re-inspections the Company achievement translation expanding application scenarios and elevating the industry's overall development level.encourages suppliers to evolve from transactional partners to collaborative partners continuously enhancing supply Leveraging its multi-omics technology platforms clinical research resources and global service network the

chain co-innovation capabilities and quality co-governance. Company actively engages with industry associations medical institutions research institutes academic alliances

BGI Genomics' supplier communication and cooperation mechanism and international partners continuously deepening collaboration in technical exchange expert consensus building

industry-academia-research synergy and international cooperation. This accelerates the transition of frontier life

science technologies from research exploration to clinical application public health practice and inclusive health

Supplier technical Arrange supplier technical exchanges to jointly advance technological innovation and quality services continuously injecting momentum into standardized industry development and precision medicine

exchanges improvement. ecosystem building.BGI Genomics' sector collaboration management measures and achievements

Framework agreement Prioritize framework agreements for high-spend or high-frequency procurement categories to reinforce

cooperation long-term collaboration. Building a collaborative network in the sector

BGI Genomics continues to expand its collaborative network operating in over 100 countries and regions globally.Negotiation It partners with over 2000 research institutions and 2400 medical institutions in China including more than 600

and bidding Standardize communication and selection through quotation comparison competitive negotiation

communication and procurement bidding.Grade-A Tertiary hospitals and collaborates with over 3000 overseas medical and research institutions having

established relationships with health authorities in more than 30 countries and regions.Medical institution collaboration and localized implementation

Joint on-site visit and Conduct cross-departmental on-site exchanges focusing on production capacity quality service and

exchange technical compatibility. BGI Genomics continues to advance localized implementation in hospitals having established partnerships with

over 2400 medical institutions in China including more than 1000 collaborating through the localized laboratory

model. The Company continuously upgrades its SIRO high-throughput gene testing AI+ localized solution which now

Case Host the "Inclusive Technology for a Healthy Life" conference to promote co- provides technical support for multiple testing products including non-invasive prenatal testing (NIPT) and CNV-seq.study construction of a precision health ecosystem

Clinical research and technical collaboration

In March 2025 BGI Genomics participated in the first Healthy Partners BGI Genomics has partnered with multiple leading medical institutions nationwide to launch a multi-center study

Conference hosted by BGI Group at the BGI Center inviting over on PTseq targeted high-throughput sequencing for mycobacteria and initiated a clinical multi-center study on

400 strategic distributors partners and industry representatives PTseq Plus targeted high-throughput sequencing for pathogenic microorganisms with over 20 domestic medical

nationwide. The event systematically showcased achievements institutions. As of the end of the reporting period PMseq and PTseq products have delivered over 560000 tests to

in precision health cell storage smart handheld ultrasound and clinical patients.home health monitoring with on-site signing of agreements with Professional training and capacity empowerment

approximately 30 partners. The conference facilitates the extension

BGI Genomics organizes comprehensive training on the full workflow of high-throughput sequencing for pathogenic

of cutting-edge life science technologies into household settings and microorganisms and continuously delivers specialized training for KOL clients on topics including pathogenic

public health services deepens industrial synergy and ecosystem co- microorganisms CNV-seq carrier screening and WES. This enables partners to develop dry-lab testing and analysis

construction and promotes the dissemination of proactive health capabilities enhancing their comprehensive service delivery and professional standards for end users.concepts and the practical application of scientific and technological The first Healthy Partners Conference hosted by

BGI Group Key specialty collaboration and clinical application

innovations.In oncology diagnosis and treatment BGI Genomics collaborates with over 500 Grade-A Tertiary hospitals in China

and has successfully piloted multiple oncology high-throughput sequencing laboratories delivering over 290000

Key performance tumor-related genetic tests. In chronic disease management the Company partners with nearly 100 Grade-A Tertiary

hospitals and has provided genetic testing for hereditary cardiovascular diseases to over 5000 individuals through

Indicator Unit 2025 data multi-center programs.Public welfare projects and public health collaboration

Total number of company suppliers Counts 2180

BGI Genomics continues to advance the implementation of public welfare programs based on genetic testing having

Localization ratio % 78 launched over 120 such initiatives across more than 20 provinces autonomous regions and municipalities with

Local procurement ratio % 96 cumulative screenings exceeding 30 million individuals. Among these a newborn genetic screening service program

was launched in Ordos and a free colorectal cancer screening project was implemented in Shijiazhuang.

77 78BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Case Deepening industrial synergy to advance innovative brain health diagnostics and Case Launching the i99 Smart Health System to advance the precision health management

study therapeutics study model

In March 2025 BGI Genomics signed a cooperation agreement with Vazyme to deepen collaboration in life sciences In April 2025 BGI Genomics launched the "i99 Smart Health" multi-omics health management system at the 13th

and in vitro diagnostics focusing on early screening precision diagnosis and treatment and efficacy evaluation West Lake International Medical Forum. The Company systematically articulated a new paradigm for precision

for chronic diseases such as Alzheimer's disease and promoting coordinated implementation of technology R&D health management and in collaboration with over ten institutions established a "Precision Health Management

product application and clinical translation. This partnership helps integrate domestic industrial chain resources Consortium" while simultaneously initiating expert consensus development on multi-omics health management.refine integrated brain health solutions and enhance capabilities for early detection and precise intervention of This initiative accelerates the translational application of multi-omics technologies in health management settings

related diseases. and drives the industry's evolution from traditional physical examinations toward a more precise proactive and

personalized health management model.On-site view of the 13th "West Lake International Medical Forum"

Case Releasing genetic data products and deepening strategic collaboration to drive value

study realization from precision medicine data

In June 2025 BGI Genomics entered into a strategic collaboration with the Shenzhen Data Exchange and launched

its first precision medicine data products: the "Hereditary Tumor Variant Knowledge Base" and the "Tumor Somatic

Signing ceremony of the cooperation agreement between BGI Genomics and Vazyme Mutation and Drug Therapy Knowledge Base." This initiative pioneers the deep integration of genomic data assets

with precision diagnosis and treatment scenarios filling a domestic gap in tumor precision medicine data products

Case and offering a new pathway for compliant medical data circulation data value realization and innovative upgrading Supporting the International Conference on Genomics to promote collaborative

study development of maternal and child health of the biopharmaceutical industry.In April 2025 BGI Genomics supported the Symposium on

Clinical Applications in Reproductive Health at the 20th

International Conference on Genomics held in Shenzhen. The

event brought together over 30 global experts in maternal

and child health and attracted nearly 60000 participants

online and offline. Discussions centered on breakthroughs

in genetic testing technologies innovative multi-omics

applications and optimization of birth defect prevention and

control. The symposium also launched two industry standard

development projects for clinical interpretation guidelines On-site view of the Symposium on Clinical Applications in Reproductive Health at the 20th International Conference on

contributing to enhanced maternal and child health services Genomics

and standardized sector development. On-site view of the strategic collaboration signing and product launch ceremony between BGI Genomics and the Shenzhen Data Exchange

79 80BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Green Innovation for Shared

Ecological Benefit

3

BGI Genomics regards green development as an intrinsic requirement for high-quality corporate growth. Deeply

aligned with ecological civilization China's "dual carbon" goals and global sustainability trends the Company

integrates the principles of respecting adapting to and protecting nature throughout its business management and

value creation processes. Environmental management is upheld as essential to maintaining compliance baselines Environmental compliance Energy management and

and ensuring stable operations. The Company continuously improves resource allocation efficiency enhances management circular economy

developmental resilience and builds long-term core competitive advantages. Looking ahead BGI Genomics will

further advance the synergistic co-creation of economic environmental and social value solidifying its green Addressing climate change Ecosystem and biodiversity conservation

foundation through more responsible practices and contributing corporate strength to building an eco-friendly

society and achieving harmony between humanity and nature. Pollutant and waste management

81 82BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Environmental compliance management BGI Genomics' environmental compliance management governance structure

CEO (Ultimate *O versees the overall environmental and energy management functions of the

Responsible Person)

BGI Genomics strictly complies with laws and regulations including the Environmental Protection Law of the Company.People's Republic of China the Water Pollution Prevention and Control Law of the People's Republic of China the EHS Management

Air Pollution Prevention and Control Law of the People's Republic of China and the Law of the People's Republic *Coordinates company-wide environmental and energy management.Committee

of China on the Prevention and Control of Environmental Pollution by Solid Waste. The Company closely monitors

evolving environmental regulations to ensure full compliance. It systematically embeds environmental protection

*T he general manager is responsible for implementing environmental protection

resource conservation and green operations into all stages of R&D production testing and laboratory management plans monitoring pollutant emissions conducting facility inspections liaising with

progressively establishing an integrated environmental management system that links institutional constraints Environmental regulators managing emergencies organizing training and maintaining records.organizational implementation risk identification monitoring and control and emergency response—thereby Protection Working Group * The environmental protection supervisor is responsible for implementing

enhancing corporate reputation and market competitiveness. environmental protection plans monitoring pollutant emissions conducting

facility inspections liaising with regulators managing emergencies organizing

Governance training and maintaining records.BGI Genomics has established core policies such as the Environmental Management Manual and Waste Management Strategy

Procedures supplemented by supporting documents including the Quality Environment and Occupational Health

& Safety Management Manual Laboratory Waste Management Regulations and Waste Disposal Management BGI Genomics consistently integrates environmental compliance into business management through the lens of

Regulations. The Company continuously refines its environmental management requirements pollution prevention "maintaining compliance baselines preventing risks enhancing capabilities and enabling transformation." The

measures and emergency response capabilities advancing environmental management beyond baseline Company identifies and assesses key environmental compliance-related risks and opportunities across critical

compliance toward refined routine and green operations. Environmental compliance is treated as a critical operational scenarios—including pollutant control hazardous chemical management standardized waste disposal

foundation for stable operations and mitigating environmental liability risks. Through alignment of group-level stable facility operations emergency preparedness and green laboratory initiatives—and aligns these with

mandates with on-site execution by subsidiaries the Company ensures environmental responsibilities are effectively operational stability cost control brand reputation and sustainability objectives. This approach shifts environmental

assigned to organizations systems facilities and individual roles. compliance from passive adherence to proactive capability building.BGI Genomics' identification and response strategies for environmental compliance-related risks and

opportunities

Risk/

opportunity Specific description Impact duration Financial impact Response strategytype

Risk

Environmental regulations pollutant

discharge management hazardous *C ontinuously update

Compliance waste transfer and environmental Increased costs for policy documents;

and emergency response requirements Medium- compliance remediation; *I mplement pollutant

supervision continue to tighten. Inadequate and long- potential risk of discharge registration and

risks implementation of systems term administrative penalties. filing management;

recordkeeping or filing maintenance *S trengthen training and

may result in compliance gaps. record retention.Increased costs in facility *E stablish routine

Operational Malfunctions in wastewater and inspection and third-party

risks of exhaust gas treatment facilities or Short

upkeep and emergency

handling; higher testing mechanisms;

pollution associated monitoring and emission and equipment may cause abnormal medium expenditures on retesting

*E nhance malfunction

control discharges or service interruptions term and remediation; partial

contingency plans;

facilities *S trengthen engineering disrupting normal operations. disruption to production operations. patrols and facility maintenance.BGI Genomics certified with ISO 14001 Environmental Management System

83 84BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Risk/ Emergency response to environmental safety risks

opportunity Specific description Impact duration Financial impact Response strategytype BGI Genomics has developed documents including the Emergency Response Plan for Environmental Emergencies

and consistently treats environmental emergency management as critical support for mitigating environmental risks

ensuring stable operations at key sites and safeguarding environmental safety baselines. By refining mechanisms

Processes involving chemical use Increased costs for for early warning response incident handling reporting and post-event review the Company shifts environmental Risks in compliant hazardous Enforce strict classification

hazardous waste liquid collection temporary waste disposal; packaging and labeling; risk management from reactive post-incident responses toward an integrated approach of pre-incident prevention

chemicals storage of medical waste and Short hazardous waste transportation carry and Higher expenses for standardize temporary in-incident control and post-incident improvement. This continuously enhances rapid response and coordinated and

hazardous risks of environmental contamination medium

incident response and storage areas; engage

cleanup; qualified third parties incident handling capabilities at critical facilities providing assurance for environmental compliance and business

waste and secondary incidents. Poor term continuity.management management may lead to leaks loss

Potential increase for disposal; conduct

or secondary pollution. in liability-related specialized drills.expenditures. Case Conduct chemical spill emergency drills to enhance on-site response and coordinated

study handling capabilities

In June 2025 the Company conducted an emergency drill simulating a dilute sulfuric acid spill causing injury. The

Events such as thunderstorms Increased investment in Establish a three-tier exercise covered the full response process—including incident reporting site cordoning reagent containment

Risks from extreme heat and flooding may Short emergency supplies and early warning and graded medical aid and personnel assembly—with all response teams arriving within three minutes and properly wearing

natural disrupt facility stability and heighten and rescue operations; response mechanism; protective gear. The drill effectively validated the feasibility of the chemical

disasters and environmental management risks medium Higher facility repair enhance the environmental

emergencies related to wastewater exhaust gas term costs; increased expenses emergency response plan; spill emergency plan enhanced on-site coordination and safety protection

and hazardous waste storage. for operational recovery. conduct realistic drills. capabilities and laid the groundwork for improving protective inspections and

external coordination mechanisms.Opportunities

Advancing "zero-waste laboratories"

Opportunities green offices energy-saving retrofits Reduced energy and Medium- operational costs; lower Promote green laboratory in green and resource conservation helps and long- resource consumption; initiatives; advance source laboratory reduce operational consumption term improved management reduction and classified construction and enhances the precision of efficiency. management.environmental management.On-site view of the chemical spill emergency response drill

Standardized environmental

management compliant emissions Enhanced partnership Continuously disclose Brand and

market and continuous improvement

Medium- trust and brand value; environmental performance; In 2025 the Company's total investment in environmental management was RMB 1.2195 and long- address ESG rating gaps;

opportunities enhance trust among customers term Reduced reputational regulators and investors damage risks. enhance verifiability of management systems. million with no administrative penalties imposed by the Ministry of Ecology and Environment strengthening ESG performance.or other relevant authorities due to environmental incidents;

A total of 17 emergency drills for sudden environmental risk incidents were conducted covering

Impact risk and opportunity management

BGI Genomics has established management procedures such as the Environmental Aspect Identification Evaluation 1595 participants.and Control Management Procedure and the Emergency Preparedness and Response Management Procedure.Centered on environmental safety the Company has built a comprehensive mechanism covering identification Indicator 2025 achievement status

assessment monitoring early warning response and post-incident review. Focusing on high-risk scenarios

in laboratories and production—including wastewater exhaust gas noise hazardous waste chemicals and Zero major environmental incidents throughout the year Achieved

emergencies—the Company continuously strengthens key activities such as environmental aspect identification Monitoring results for wastewater exhaust gas and noise all met

emission control third-party testing on-site inspections and emergency drills advancing environmental risk Achievedemission limit requirements

prevention and management capability in tandem.

8586

Key performanceBGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Pollutant and waste management BGI Genomics' waste recycling and utilization management measures

Classification and identification

BGI Genomics places high priority on managing toxic emissions and waste. The Company has established policy

documents including the Laboratory Environmental Monitoring Management Regulations Exhaust Gas Wastewater

and Noise Management Procedures and the Quality Environment and Occupational Health & Safety Management BGI Genomics' subsidiary Wuhan Biotechnology distinguishes recyclable from non-recyclable items in

Manual to strengthen end-to-end control of wastewater exhaust gas noise and waste. By focusing on key its policies

processes—classified collection standardized temporary storage compliant discharge outsourced disposal and Recyclable items refer to uncontaminated materials with recycling value

third-party monitoring—the Company extends pollution and waste management beyond point-in-time compliance Non-recyclable items refer to uncontaminated materials without recycling value

toward full-process traceability inspectability and continuous improvement solidifying the environmental safety

foundation in laboratory and production settings.Classified collection

Waste disposal and management

BGI Genomics has formulated policy documents including the Laboratory Waste Management Regulations Solid General solid waste is centrally collected by category and placed in designated areas

Waste Management Procedures Hazardous Chemicals Management System Experimental Hazardous Chemical Hazardous waste medical waste and liquid waste are classified packaged labeled and temporarily

Waste Management Process and Waste Disposal Management Regulations to strengthen full life-cycle waste stored as required

management—from generation classification and packaging through temporary storage transportation and final Mixing co-loading or random disposal of different waste categories is strictly prohibited

disposal. Aligning with management requirements for medical waste chemical waste liquid waste and general

solid waste in laboratory and production settings the Company advances waste governance from compliant

disposal toward source reduction standardized handling and auditable recordkeeping continuously reinforcing

Recycling and disposal

environmental safety foundations and supporting "zero-waste laboratory" initiatives and green operations.BGI Genomics' waste classification management measures Other solid waste is legally transferred to capable entities for recycling and disposal

General waste is uniformly collected and disposed of by the park or municipal sanitation system

Hazardous waste is legally transferred to qualified entities for utilization and disposal

General waste Hazardous waste Classification and identification

*Dispose by category; mixing with *Classified collection of infectious waste sharps chemical

medical or chemical waste is strictly waste liquid waste and waste organic solvents BGI Genomics' subsidiary Tianjin Medical Testing Laboratory advances "zero-waste laboratory"

prohibited *Use dedicated packaging or sealed containers for storage with construction

*After centralized collection by standardized labeling BGI Genomics' subsidiary Wuhan Biotechnology replaced foam inserts in NIFTY test kits with paper pads

departments place in designated *Establish hazardous waste temporary storage rooms with at its IVD production site

areas or containers time-limited storage and dedicated personnel management as Reduce process waste generation through packaging optimization and standardized management

*Collected and disposed of required

uniformly by sanitation authorities *After completing declaration registration or handover Compliant pollutant discharge

or the industrial park procedures transfer to qualified third parties for compliant

*Strengthen daily inspections transport and disposal The Company focuses on key aspects—pollution source identification treatment facility operation process

and cleanliness maintenance at *Maintain ledger records covering the entire process: collection monitoring and result verification—to gradually establish a pollutant discharge management mechanism

collection points temporary storage sterilization transport and handover encompassing daily control periodic testing and anomaly response. This enables key facilities to maintain

environmental compliance during stable operations supporting the Company's advancement in green operational

capabilities and refined environmental governance.

87 88BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

BGI Genomics' management measures for compliant pollutant discharge Addressing climate change

Wastewater management

BGI Genomics integrates climate change response with

* At BGI Genomics' subsidiary Wuhan Biotechnology laboratory wastewater from Building B1 is treated by an green operations energy conservation low-carbon

integrated sewage treatment unit and from Building B2 by a centralized wastewater treatment plant prior to

discharge; annual environmental monitoring in Wuhan confirms compliance for pH COD BOD5 suspended R&D stable facility operations and environmental risk

solids and ammonia nitrogen; mitigation. The Company closely monitors evolving

*G eneral wastewater at BGI Genomics' subsidiary Tianjin Medical Testing Laboratory undergoes quarterly requirements and challenges under China's "dual carbon"

third-party testing with all results meeting emission limits. goals regarding corporate transformation and physical

climate risks. It has formulated the Carbon Emission

Management Measures extending energy-saving

Waste gas management emission-reduction and green transition principles across

the full life cycle of products and services. Subsidiaries

* At BGI Genomics' subsidiary Tianjin Medical Testing Laboratory volatile organic compounds from nucleic are actively implementing energy-saving and emission-

acid extraction are treated using a "filter + UV photocatalytic oxidation + activated carbon adsorption"

system; reduction projects and environmental equipment and

* At BGI Genomics' subsidiary Wuhan Biotechnology exhaust from the B1 quality inspection area and B2 pilot processes are prioritized in facility construction and

testing area is collected and treated via activated carbon adsorption before discharge; Wuhan monitoring equipment procurement—enhancing energy efficiency BGI Genomics' non-invasive prenatal genetic testing service

data confirm that total non-methane hydrocarbons and formaldehyde meet regulatory limits; while reducing carbon emissions and advancing low- obtained a Product Carbon Footprint Verification Statement

*Key emission points are included in routine inspections and monitoring programs. carbon product management.Identifying climate change risks and opportunities

Noise management BGI Genomics continues to integrate climate change into core green operations and low-carbon transformation

strategies. Across the full life cycle of laboratory operations production delivery facility construction and product

*B GI Genomics' subsidiary Wuhan Biotechnology implements sound insulation vibration damping and services the Company identifies climate-related risks and opportunities affecting operational stability energy costs

noise attenuation measures for noise sources such as ultrasonic cleaners and HVAC units; daytime and environmental management and green development. Key focus areas include physical risks from extreme weather

nighttime noise levels at the IVD facility boundary comply with Class 2 standards; disrupting environmental infrastructure and lab environments transformation opportunities from energy efficiency

*B GI Genomics' subsidiary Tianjin Medical Testing Laboratory maintains routine noise control in

and low-carbon R&D and the positive impact of green products and operations on brand image customer trust and

laboratories with an annual average of approximately 55 dB meeting emission limits.long-term competitiveness. Climate change management is evolving from conceptual awareness toward project

implementation and performance validation.BGI Genomics' climate change risk and opportunity identification results

Key performance

Risk/

opportunity Specific description Impact duration Financial impact Response strategy

Indicator Unit 2025 data type

Risk

Total amount of hazardous waste generated Tonnes 136.56

? Develop a Group low-carbon

Total hazardous waste generated per RMB 100 million in revenue Tonnes 3.69 National and local policies on transition roadmap and integrate

low-carbon transition carbon carbon management across the full

reduction and biodiversity Increased compliance life cycle of R&D production and

Total exhaust gas emissions Cubic meter 1864328.6 Policy and conservation continue to Long- costs penalty expenses supply chain

legal risks tighten; failure to comply term and risk of international ? Monitor domestic and international

Total amount of wastewater discharge Tonnes 6722.75 promptly may result in revenue decline climate policy updates conduct

regulatory restrictions fines or carbon compliance training

project approval delays and establish a carbon footprint

Total water withdrawal Tonnes 66140 accounting system

89 90BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Risk/

opportunity Specific description Impact duration Financial impact Response strategy

Energy management and circular economy

type

? Establish a climate disaster early BGI Genomics strictly adheres to the Circular Economy Promotion Law of the People's Republic of China and related

Extreme heat floods

warning mechanism and share regulations. It has established policy documents including the Energy and Resource Consumption Management

earthquakes and other disasters Facility repair costs

information with meteorological

can damage laboratories revenue losses from Procedure and Energy Conservation Management System embedding energy management and circular economy

Acute and emergency management

biobanks and cold-chain Short- business interruption principles throughout business operations. The Company aligns resource and energy allocation with green

physical authorities

logistics facilities leading to term emergency response development requirements balancing energy efficiency resource intensity and process reduction outcomes. This

risk ? Enhance off-site disaster recovery

data/sample loss and disruption and sample

systems for samples/data conduct enhances operational resilience to resource and environmental constraints fostering a greener more resource-

of production/sequencing preservation expenses

regular emergency drills and efficient and sustainable development model that supports long-term stability and high-quality growth.services

assess infrastructure resilience gaps

BGI Genomics' energy utilization management measures

Ongoing climate warming ? Adjust research portfolios and

and ecological shifts alter Increased R&D strengthen sequencing and early-

pathogen distribution and realignment costs warning research on emerging

Chronic sample collection environments higher sample infectious and climate-sensitive

Long-

physical reshaping disease profiles and acquisition expenses diseases Policy and accountability Control of key energy- Metering monitoring and Energy-efficient operations

term

risk research priorities; drought/ fluctuating water costs ?A dvance water-saving retrofits and implementation consuming processes analysis optimization

water scarcity in supply chain and risk of project water recycling systems in labs;

regions affects production water termination optimize ecological resilience of Establish the Energy Prioritize natural Implement Optimize HVAC

reliability global sample collection sites Conservation lighting meter reading cooling and

Management System Use LED energy- management heating systems

Opportunities Assign energy-saving efficient lighting Compile Improve energy

responsibilities Turn off equipment monthly energy utilization

Climate change drives demand ? Develop diagnostic kits for climate- for key areas when unattended consumption efficiency

for emerging infectious disease related diseases and environmental (common areas Operate air reports Reduce air

Product surveillance sequencing of genomics monitoring solutions production QA conditioning on- Analyze anomalies conditioning

Medium- Revenue growth brand

and service climate-sensitive conditions ? Create "climate health + gene

and long- premium and new R&D warehousing) demand with and report findings costs in common

innovation and environmental genomics technology" service models

term market expansion and appoint an temperature in regular meetings areas

opportunities monitoring—creating growth and participate in national and overall energy controls Develop additional

opportunities for related testing international climate-health

and research services research initiatives conservation lead to energy-saving

ensure departmental measures based on

and role-level anomaly analysis

? Advance photovoltaic retrofits implementation

in campuses and procure green

Opportunities Increase clean energy use to

power for data centers to increase

in energy reduce carbon emissions from Long- Lower energy costs and

renewable energy share

structure labs and data centers and term improved cost stability

?O ptimize lab energy consumption

optimization mitigate energy price volatility Resource utilization and circular economy

and deploy high-efficiency

equipment BGI Genomics continues to integrate resource efficiency enhancement and circular economy principles into its green

operations framework shifting resource management from basic operational support toward a balanced focus

Proactive climate action

Brand and Lower financing costs ?D evelop brand cases showcasing on efficiency gains cost optimization and environmental value creation. Centered on laboratory and production

enhances corporate ESG

ESG Long- stronger customer "gene technology empowering operations the Company adopts a full-process management mindset to coordinate resource conservation source

performance and builds trust

opportunities term loyalty reduced market climate adaptation" to enhance reduction and standardized utilization—continuously strengthening awareness of resource constraints and refining

with investors customers and

access barriers corporate social value

the public management capabilities to drive a more intensive low-consumption and sustainable development model laying a

solid foundation for green transformation and long-term resilience.

91 92BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

BGI Genomics' key resource management measures 关键

绩 In 2025 total energy consumption was 2439.47 tonnes of standard coal.Management 效

scope Key management measures

And purchased electricity amounted to 19849241 kWh.Water *User departments conduct daily inspections of water fixtures in labs and production areas and promptly

conservation report leaks to the engineering department;*The property management team inspects water fixtures in common areas daily and repairs leaks

management immediately.*Maximize natural lighting; avoid artificial lighting when natural light suffices;

*Use LED energy-efficient lamps to reduce energy consumption and extend service life;

*Turn off personal computers monitors and meeting room equipment (projectors audio systems) when

Energy leaving;

conservation *Select energy-efficient office equipment such as ENERGY STAR computers printers and air conditioners;

management *Air conditioning in common areas is user-activated on demand with summer settings no lower than

26 ° C and winter settings no higher than 28 ° C. In 2025 BGI Genomics' subsidiary Wuhan Biotechnology's

IVD production site is projected to save approximately RMB 300000 annually by discontinuing the park's

centralized HVAC system and switching to Hitachi lab units for heating/cooling.Ecosystem and biodiversity conservation

*Promote double-sided printing reduce document printing volume and encourage electronic document BGI Genomics integrates its business characteristics into environmental impact control during operations engaging

Green office circulation and storage to conserve resources; in ecosystem and biodiversity conservation. Through pollution prevention standardized waste handling risk *Leverage digital platforms; use DingTalk or Tencent Meeting for training and conferences to enable mitigation and green operations the Company minimizes disturbances from laboratory and production activities on

paperless operations and achieve energy savings and emission reductions.surrounding environments.Meanwhile leveraging its technological strengths the Company advances environmental innovation by exploring

biotechnological applications in pollution remediation—such as bioremediation for soil and water purification—and

employs gene sequencing to monitor ecosystem health.

93 94BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

People-Oriented: Inclusiveness for

the Common Good

4

BGI Genomics deeply embeds social responsibility throughout its corporate development anchoring its

commitments in safeguarding public health protecting employee rights and promoting inclusive industry growth.Adhering to a people-centered philosophy the Company has built a full-cycle employee care system covering hiring Employee employment Protection of employee rights

rights protection training and development and occupational health and safety—ensuring employees' legitimate

rights and enabling shared growth with the organization. Simultaneously leveraging its core expertise in genomics Employee training and development Occupational health and safety

BGI Genomics advances medical accessibility and equitable healthcare extending cutting-edge genetic technologies

to broader populations and actively fulfilling its corporate social responsibility to support Healthy China and societal Medical accessibility and equitable healthcare

sustainability.

95 96BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Employee employment By rank By educational attainment

BGI Genomics steadfastly upholds its "people-first" philosophy strictly complying with the Labor Law of the People's 20 219 134

Republic of China and related regulations and resolutely prohibiting child labor forced labor and employment 493

discrimination. The Company has established a compliant employment management system spanning the full 1086

employee lifecycle—from onboarding and attendance to contract fulfillment. Centered on the Employee Handbook

it has developed a comprehensive policy framework signed labor contracts with 100% of employees and lawfully 1081

contributed to the five social insurances and housing fund. Upholding principles of diversity and equal opportunity

BGI Genomics attracts professionals from diverse backgrounds building a robust talent foundation for innovative

growth on a platform of compliant operations. 2260

Employee composition 1867

Number of senior management employees Number of employees with doctoral degrees

Number of middle management employees Number of employees with postgraduate degrees

Total number of employees Number of junior management employees Number of employees with a bachelor's degree

Number of general employees Number of employees with junior college degrees or below

3580

Compliance and diversified employment management system

Including: Number of newly hired employees

Anti-child labor and Anti-discrimination

forced labor and diversity

348

*The Employee Handbook contains a strict *The Company fully integrates the principles

requirement that all job applicants must of diversity equity and inclusion (DEI) into

be at least 18 years of age; those under 18 all stages of the employment lifecycle. The

are automatically deemed ineligible for Employee Handbook explicitly prohibits

employment thereby eliminating child any form of discrimination including

By gender By age labor risk at the recruitment source; but not limited to discrimination based

All forms of forced or compulsory labor on legally protected characteristics such

38 人 *are strictly prohibited. The Company as race color sex age religion national

safeguards employees' personal freedom origin disability marital status veteran

2056 人 and right to voluntary employment

status sexual orientation or gender

throughout the entire hiring and identity.

1219 人 management process and has established *As of the end of 2025 the Company

a routine monitoring mechanism. employed 55 international staff from

1524 人 25 countries and 16 employees with

disabilities achieving a diverse and

inclusive workforce.

2323人

关

键 In 2025 the labor contract signing rate for full-time employees was 100%.Number of employees aged 30 and below 绩

Number of male employees 效Number of employees aged 30 to 50 No confirmed incidents of discrimination child labor or forced labor occurred.Number of female employees Number of employees aged 51 and above

97 98BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Protection of employee rights Employee care and communication

Employee care and two-way communication serve as vital links for BGI Genomics in fostering harmonious labor

Protecting employee rights is a cornerstone for BGI Genomics to attract talent and achieve sustainable development.The Company places employee rights at the heart of its management philosophy and has built a comprehensive relations and cultivating a positive workplace culture. The Company follows a labor dispute resolution principle

multi-tiered and human-centered protection system covering core needs across the entire employee career lifecycle of "prioritizing amicable negotiation followed by internal mediation with legal recourse as a last resort" lawfully

through four dimensions: compensation and benefits communication and care grievance response and hardship addressing employee concerns to maintain stable labor relations. Communication channels—including employee

support. Through a competitive and caring compensation and benefits framework the Company safeguards labor forums suggestion boxes and internal platforms—are established to routinely gather feedback. Leveraging the labor

rights; it listens to employee voices via diverse communication channels refines management practices through union the Company builds a diversified platform for cultural and recreational activities and periodically launches

scientific survey mechanisms and conveys corporate warmth through a regularized support system—thereby interactive welfare initiatives to enrich employees' lives and strengthen their engagement and sense of belonging

upholding employees' legitimate rights and enhancing their sense of belonging well-being and identification with

the Company. ensuring humanistic care permeates every stage of their career journey.Compensation and benefits protection Case Rapid response to employee accidents and timely insurance payout to reinforce study support mechanisms

With the Employee Handbook as its institutional core the Company strictly adheres to the principles of "position- In 2025 an employee suffered a severe traffic accident while cycling colliding with a motor vehicle resulting in

based grading grade-based pay person-job fit and pay adjustment upon position change" establishing an

integrated four-component compensation and benefits system comprising "fixed salary + variable performance pay + injuries classified as Grade 10 disability. Immediately after the incident the Company activated its commercial

long-term incentives + diversified benefits." The compensation structure is position-based and performance-driven insurance claims assistance process assigning a dedicated coordinator to manage all steps—from initial reporting

ensuring high performers are highly rewarded. For key talent long-term incentive plans—including employee stock to final settlement—providing comprehensive support. In addition to statutory compensation the employee

ownership and restricted stock units—are implemented to align employee and corporate interests for shared growth. successfully received a RMB 30000 disability payout under the commercial accident insurance policy. This financial

Concurrently the Company continuously enhances supplementary protections such as commercial insurance support significantly aided the employee's subsequent rehabilitation fully demonstrating the protective function of

holiday benefits and expatriate allowances to comprehensively safeguard employee rights and enable them to share the Company's commercial insurance program and reflecting BGI Genomics' commitment to humanistic care and

in the Company's success.safety-net support.Commercial insurance protection Life support benefits Employee satisfaction surveys

* Coverage includes group accident insurance and *Holiday benefits are distributed during the Spring The Company has established a dual-dimensional employee satisfaction survey system. Annual surveys are

overseas business travel insurance effectively filling Festival International Women's Day and Mid-Autumn conducted regularly to comprehensively assess employee perceptions across key areas including corporate

gaps in statutory social insurance and providing Festival; management compensation and benefits and career development. Daily pulse surveys are embedded throughout

financial support to employees affected by accidents. *Dedicated team-building budgets are allocated to each employee service touchpoints to capture real-time feedback. Based on insights the Company operates a closed-loop

department to enrich employees' extracurricular lives;

*Dedicated nursing rooms are provided for pregnant "survey–analyze–improve–feedback" management mechanism and provides special recognition for constructive

and lactating female employees; employee suggestions. Guided by genuine employee needs the Company continuously refines its management

*An employee gym is open offering fitness programs to systems driving mutual enhancement of employee experience and organizational capability.comprehensively meet daily wellness needs.Employee satisfaction survey mechanism

Special

non-statutory Annual systematic survey (overall evaluation)

benefits A comprehensive annual satisfaction survey is conducted each year focusing on four core dimensions: business

*Provides employees with one new non-cumulative paid *Innovatively launched the "Huayitong" program providing satisfaction service evaluation metrics online service platform assessment and improvement suggestions.sick day per month; full-time employees and their spouses and children

*Employees with one full year of service are entitled to with end-to-end solutions for major disease prevention

3 days of paid family visit leave. Those who do not take diagnosis treatment rehabilitation and medical expense Daily routine survey (real-time evaluation)

the leave may receive a family visit subsidy of up to RMB reimbursement; Real-time satisfaction surveys are administered following each service delivered by the Company's HR Shared

1500. *The "Employee Gene Mall" continues to operate offering Service Center focusing on core dimensions such as response efficiency service attitude and digital intelligence

*Parental and caregiving leaves compliant with full-time employees and their immediate family members level—enabling immediate quality monitoring dynamic follow-up and a continuous service oversight mechanism.local government regulations are provided with five complimentary genetic testing slots annually

clear guidelines covering accrual application and extending the Company's genomics expertise to employee Dynamic iteration

calculation procedures. welfare. The survey system undergoes continuous optimization and expansion. Offline QR code rating channels have been

Comprehensive leave protection Special health benefits added for scenarios such as onboarding/offboarding and talent applications and the survey scope has been

extended nationwide to achieve full coverage across both service scenarios and geographic regions.

99 100BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

关

键 In 2025 annual employee satisfaction reached 4.90 (on a 5-point scale) corresponding to a Employee training and development绩

效 BGI Genomics consistently regards talent as the primary driver of innovation and development. Placing high

satisfaction rate of 98.03%. importance on employee capability enhancement and career progression the Company has built a full-cycle talent

4.88 77.22 development system that is horizontally categorized and vertically stratified. Anchored by policies such as the Job Daily employee satisfaction scored and employee engagement reached %. Qualification Management System and Training Management System it has established a dual-track "management

+ professional" career path to break through developmental ceilings. A layered role-specific training system

integrating learning with real-world application provides targeted growth opportunities for employees at all levels

Assistance for employees in hardship and functions aligning individual advancement with corporate strategy and fueling sustained innovation through a

steady pipeline of talent.BGI Genomics has established a standardized employee hardship assistance system led by the labor union with

coordinated support from HR and relevant departments. It defines multi-dimensional end-to-end support measures Career development

to provide a safety net for employees facing accidents illness or family difficulties. Through diversified initiatives— Viewing talent as the core engine of innovation the Company upholds the philosophy of "developing talent through

including commercial insurance claim assistance dedicated hardship funds and compassionate outreach—the projects and driving growth through missions" establishing a strategy-aligned systematic and closed-loop talent

Company delivers financial aid practical support and psychological counseling to address employees' urgent needs development mechanism. Precisely mapping core competencies required for strategic execution it has built an

ensuring every individual feels the Company's care and warmth. end-to-end career development framework covering talent standards assessment systems decision-making

planning cultivation pathways and career tracks. Key practices include: defining competency benchmarks through

Assistance measures for employees in hardship job qualification criteria; identifying high-potential talent via multi-method assessments; optimizing deployment

and development plans through talent reviews; enhancing capabilities through job rotation combined with hands-

on projects; and guiding growth through dual-track career paths—ensuring talent development keeps pace with

business evolution and solidifying the Company's talent foundation.Talent cultivation system

Deliver Offer job Provide Conduct

financial coordination one-on-one periodic BGI's Grand Vision

assistance and employment psychological follow-up visits

through information counseling with assisted Type Curriculum system Curriculum system

dedicated tailored to the and emotional individuals

hardship funds employee's support 1. Leadership development Eagle Program Xing Program Super

and temporary and family's Management 2. High-potential talent cultivation Stem Cellcompetency

subsidies circumstances enhancement Cultivation of "International Iron Triangle" Capability reserves of management teams for global expansion

/ Overseas JV operations leaders

* Product knowledge Sales competency

training enhancement

Talent

development Professional

programs competency R&D Production Marketing Support Latest industry General competency track trends developmentenhancement

关 "Three-All" training Classic case library

键 In 2025 the Company invested over RMB 1.31 million in employee commercial insurance premiums Role-specific onboarding: History and culture + Company policies and

绩 Experienced hire – New employee New hire business overview + Product self-study assessment + Mentorship training

效 achieving 100% coverage; development

plan Spreading Wings training: Corporate history and culture + BGI business Campus recruitment – Spreading Wings

immersion + Executive dialogues + Team integration Program

During the reporting period (January 1 2025 to December 31 2025) no employees met the criteria for Training

hardship assistance * resource Platform management Course management Instructor management Funding managementsystem Peer Academy Development delivery recording Certification empowerment publication and promotion promotion and incentives Budgeting and expenditure review

Therefore no actual assistance cases occurred. Training * operations Training operations management system: Needs analysis program design implementation and evaluation

management

system

101 102BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Dual-track "management + professional" career development system Specialized development for young high-potential talent

Vertically structured dual tracks:

Horizontally career paths a management sequence (career

are organized into five job progression through team leadership and A high-potential talent program selects outstanding young professionals globally each year cultivating elite

families—Management organizational coordination assessed talent with multi-directional potential through strategic project immersion and rotational assignments.Technology Marketing "Management + professional" on strategic thinking leadership team Production and Support— dual-track career management and business acumen) and a

comprising 32 job categories development

system professional sequence (deep specialization and 624 positions. within a discipline assessed on technical External training

expertise innovation job contribution

and professional achievements).Training system Includes external company visits third-party training and academic coursework. Employees must submit

advance applications for external training which requires multi-level approval prior to implementation.Centered on the Training Management System and supported by specialized policies such as the Internal Trainer

Management System the Company has built a full-cycle stratified and role-based training framework that integrates

learning with real-world application. A standardized internal trainer certification and management system ensures

professional instructional quality. The "Peer Academy" digital learning platform breaks time and space barriers

offering all employees accessible bite-sized learning. Focused on three pillars—new hire integration management

capability building and technical empowerment—the Company delivers tiered development programs and

conducts business-aligned technical training embodying the philosophy of "developing talent through projects and Case

driving growth through missions." Through diversified and precision-targeted initiatives the Company enhances job study Advancing high-potential programs to build long-term youth talent capacity

proficiency and holistic competence enabling mutual empowerment between employee growth and organizational

advancement. In 2025 BGI Genomics focused on nurturing young high-potential talent

by advancing the Super Stem Cell program completing two cohorts during

Employee training program system the year. This exclusive initiative aims to cultivate young professionals with

New employee training multi-directional differentiation potential and self-renewal capabilities

building a core talent reserve for long-term growth. Deeply embodying the

A four-phase onboarding system ensures new hires rapidly integrate and achieve role readiness; "develop talent through projects" philosophy the program recruits top

Tailored onboarding programs: "Friendly Wings" for international hires "Spreading Wings" for campus young talent globally and assigns them to strategic company projects with

recruits and customized onboarding for experienced hires. significant responsibilities enabling rapid capability development through

real-world challenges and strengthening the foundation of the talent

pipeline.On-the-job employee training

Role-specific technical training: Departments deliver targeted programs on operational standards technical

skills and product knowledge aligned with business needs;

Management development: The "Flying Eagle Program" for mid-level managers focuses on strategic thinking

leadership team management and business acumen through a blended learning-and-practice model. The

"Leading Wings Program" for newly appointed frontline managers centers on role transition team leadership

and financial literacy to support their shift from "individual contributors" to "team leaders";

Company-wide foundational training: Mandatory programs on industry knowledge professional conduct

compliance and information security foster a learning organization.On-site training for the "Super Stem Cell" high-potential talent program

103 104BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Case Conducting specialized training on the SIRO integrated solution to strengthen Key performance

study employees' genomics testing expertise

Indicator Unit 2025 data

In 2025 to facilitate the implementation and deep application of SIRO technology and help employees accurately

grasp the core features and application scenarios of related instruments BGI Genomics organized a series of Total number of employee trainings conducted by the Company Sessions 477

specialized training sessions on the SIRO integrated solution for genetic testing. Aligned with practical technical Total training expenditure Ten thousand 102

needs the training innovatively combined in-depth theoretical instruction online assessments and hands- yuan

on practice in a progressive multi-modal approach. This enabled employees to rapidly master critical technical Total training hours Hours 66827

competencies significantly enhancing their practical expertise and laying a solid foundation of professional

capability for the successful rollout and advanced application of SIRO technology within the Company. Average training hours per employee Hours 16.28

Employee training coverage rate % 100

Performance feedback and appeals

Centered on the Performance Management System the Company has built a full-process closed-loop performance

management framework that deeply integrates appraisal outcomes with the entire career development chain—

including bonus allocation salary adjustments promotions and training—to realize "high performance high reward;

mobility based on merit." For employees deemed not yet competent individualized Performance Improvement

Plans (PIPs) are developed supported by targeted coaching and training. A standardized and accessible performance

appeal channel safeguards employees' right to voice concerns and protects their legitimate interests ensuring

On-site training for the SIRO integrated solution fairness transparency and credibility in performance management.Case Implementing a stratified training plan to systematically enhance management Performance goal setting Performance coaching

study capabilities

In 2025 BGI Genomics continued its "cross-system Goals are set using the OKR framework cascaded Direct supervisors and employees review goal

from departmental objectives through collaborative progress at least monthly analyzing performance

integration" management development programs— alignment between employees and direct variances designing improvement actions and

the Leading Wings Program and Flying Eagle Program— supervisors to ensure deep integration of individual providing necessary resources.applying tiered strategies by leadership level to precisely and organizational goals.enhance managerial competencies. The Flying Eagle

Program for mid-level managers uses a blended

learning-and-practice model over nine-month cycles

focusing on four capability pillars including strategic

Performance appeal Result feedback and thinking and cross-functional leadership complemented Performance appraisal

by intensive workshops value creation projects and On-site training photo from the "Flying Eagle Program"

review meetings

review presentations to drive individual growth and Employees may file an appeal Following the review direct Mid-year and year-end

within 5 business days after the supervisors hold performance performance reviews are

team performance. The Leading Wings Program for feedback meeting deadline; feedback meetings with conducted following a

newly appointed frontline managers delivers role- approved appeals take effect employees to communicate "direct supervisor evaluation

transition training through blended methods to build while unfiled appeals are results analyze strengths department head review"

team leadership and financial literacy supporting their deemed accepted. and gaps and co-develop process with department

evolution from individual contributors to team leaders performance improvement heads authorized to calibrate

and strengthening the foundation for high-performance plans. results.cohesive teams. On-site training photo from the "Leading Wings Program"

105 106BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Occupational health and safety Employee physical and mental health management measures

Leveraging its genomics expertise the Company has built a "multi-omics–based precision

health screening system." Building upon standard physical exams it integrates life-omics

BGI Genomics strictly complies with laws and regulations including the Work testing digital health records and cell preservation services from the China National GeneBank

Safety Law of the People's Republic of China and the Law of the People's to enable early diagnosis and intervention for major diseases while rigorously protecting

Republic of China on the Prevention and Control of Occupational Diseases . employee health data privacy under the highest security standards.Actively promoting a culture of health and fitness for all the Company designates its

Adhering to the principle of "safety first prevention-oriented and comprehensive Precision anniversary on September 9 as the "99 Health Festival." Annual comprehensive fitness

governance" the Company has established a holistic occupational health and physical assessments are organized in Shenzhen and eligible regions covering three dimensions: body

safety management system encompassing work safety occupational disease health composition physical function and physical fitness. Complementary activities such as hiking

prevention and physical and mental well-being and has successfully obtained management and trekking challenges are held to encourage employees to embrace healthy lifestyles.ISO 45001 certification. The Company implements a "whoever is in charge is The Company has launched the "Caring Hearts Program" mental health service brand inviting

responsible" accountability system cascading occupational health and safety professional counselors to provide psychological support on themes such as emotional

regulation self-exploration and family-of-origin dynamics;

responsibilities to every department and position. Through multi-dimensional

efforts—including system development facility provisioning training and

education emergency preparedness and health support—the Company not only The Company is certified under the ISO On-site one-on-one psychological counseling services are offered with exclusive monthly

45001 Occupational Health and Safety

fortifies a robust defense against workplace hazards and occupational diseases appointment slots covering multiple dimensions—including career development relationships Management System

but also builds a supportive ecosystem for employee well-being comprehensively Professional and family parenting and anxiety/grief support—to comprehensively safeguard employee

mental mental health.safeguarding employees' health and lives. health

services

Occupational health and work safety assurance mechanism

Case Hosting the 99 Health Festival hiking event to empower employee well-being and

study strengthen team cohesion

For high-risk roles in laboratories and production involving occupational hazards a dedicated In September 2025 to celebrate its 26th anniversary BGI Genomics simultaneously hosted the "99 Health Festival"

occupational health protection mechanism is implemented to standardize operational hiking event at its Shenzhen headquarters and regional sites advancing its commitment to employee well-being. The

Prevention procedures and provide employees with nationally compliant personal protective equipment Shenzhen main venue featured two routes—a 9.9 km wellness route and a 26 km endurance route—to accommodate

and control of

occupational (PPE); regular occupational health and safety training and emergency drills are organized. varying fitness levels. The event fully embodied ESG green principles by promoting "leave-no-trace hiking" and

disease hazards was supported by comprehensive medical aid volunteer services and shuttle transportation to ensure safety and

order. By integrating outdoor activity with teamwork the event effectively enhanced physical fitness reinforced the

corporate ethos of "I own my health" and significantly strengthened organizational cohesion.Reinforcing safety accountability across all staff: All employees sign individual work safety

responsibility agreements that clearly define departmental and role-specific safety duties

strengthening awareness and ownership through formal acknowledgment;

E nhancing emergency science communication: Specialized training on various emergency response

topics is conducted focusing on "everyone can respond" to disseminate practical knowledge and

elevate organization-wide safety literacy;

Conducting self-inspections and corrective actions: Smoking unauthorized electrical connections

improper use of high-power appliances and non-compliant equipment operation are strictly

Full-process

work safety prohibited in production and office areas; regular hazard inspections and rectifications are carried

management out and clear emergency response protocols are established to maximize protection of employee

lives;

End-to-end emergency drills: Specialized fire emergency exercises are conducted covering fire

alarm activation full evacuation high-rise firefighting ladder rescue cardiopulmonary resuscitation

(CPR) automated external defibrillator (AED) use and the Heimlich maneuver—significantly

enhancing employees' hands-on emergency response capabilities.

107 108BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Case Conducting scientific organization-wide fitness assessments to holistically empower 关

study employee well-being 键

绩 In 2025 the Company invested RMB 39700 in specialized occupational health and safety

In 2025 BGI Genomics conducted annual organization-wide fitness assessments in Shenzhen and eligible regions 效 initiatives for employees.deepening its holistic approach to employee health. Distinct from routine medical check-ups this assessment

scientifically evaluates physical capacity across a broad age range (20–79 years) using age-stratified models to

comprehensively assess body composition cardiopulmonary endurance strength flexibility and other fitness The Company organized specialized occupational disease screenings for 213 employees in high-risk

indicators. Complementary activities—including mountain hiking and trekking challenges—were organized to help positions across multiple locations to comprehensively mitigate occupational health risks.employees translate health awareness into daily practice significantly raising health management consciousness

and fostering a vibrant workplace culture. No major or higher-level work safety accidents occurred throughout the year.Medical accessibility and equitable

healthcare

Medical accessibility and inclusive healthcare are central to BGI Genomics' mission of "Omics for All" and a key

contribution to the "Healthy China 2030" strategy. Leveraging its genomics leadership the Company drives the

democratization and accessibility of advanced medical technologies. It empowers precision medicine in Belt and

Road countries and implements public health programs in China for birth defect prevention and early cancer

screening. Simultaneously it enhances primary care capacity through rare disease relief and nationwide health

education. Through innovation affordable pricing and philanthropy BGI Genomics extends precision medicine to

more people globally safeguarding universal health.Case

study Hosting multi-themed psychological salons to strengthen mental health safeguards

In 2025 the BGI Genomics Labor Union focused

on mental health management hosting nine

psychological salon sessions throughout the year

to foster positive mindsets work-life balance Expanding product accessibility Reducing healthcare costs

and creativity among employees. Centered

on core themes—emotional regulation self- *E xpanded access to genetic *I mplemented health

exploration and family-of-origin dynamics—the testing in grassroots poverty alleviation projects

salons innovatively blended lectures interactive healthcare settings to providing free or subsidized

games art and writing. Professional counselors strengthen local service genetic testing services to

were specially invited to guide participants in capacity; underserved regions;

exploring inner worlds listening to psychological * Delivered mobile medical

needs and addressing personal challenges. *C onducted public health services to improve

Through evidence-based psychological insights science outreach to healthcare accessibility.and experiential engagement the salons helped enhance awareness and

employees effectively manage emotions restore understanding of genomics;

mental-physical equilibrium solidify mental

health resilience and cultivate an uplifting

workplace psychological climate.

109 110BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Belt and Road Initiative Healthcare accessibility

Case Empowering precision medicine in Central Asia and advancing equitable genomics Case Participating in centralized procurement of genetic testing services and securing

study along the Silk Road study insurance reimbursement to significantly reduce public healthcare costs

In 2025 BGI Genomics through its Uzbekistan joint venture In 2025 BGI Genomics actively engaged in national centralized procurement policies driving price adjustments to

Genscreen deployed advanced genomic technologies in lower the cost of genetic testing through volume-based pricing and improving access to birth defect prevention

Central Asia to support inclusive healthcare and improve services. The Company participated in Jiangsu Province's NIPT centralized procurement—the nation's first for

medical access. The lab led a pilot newborn genetic diagnostic services—achieving multiple systemic breakthroughs. Prices dropped by over 70% and as of January

disease screening program implementing NOVA inherited 2025 NIPT was officially included in Jiangsu's Class B medical insurance with minimal out-of-pocket costs benefiting

metabolic disorder screening and NIFTY non-invasive hundreds of thousands of families annually. In Guangdong the Company supported a 62.7% price reduction for NIPT

prenatal testing (NIPT) enabling early diagnosis of multiple and advocated for its inclusion in maternity insurance enabling insured pregnant women to access the service at

treatable rare diseases and securing critical treatment "zero out-of-pocket" cost. Implemented across multiple Pearl River Delta cities this policy has substantially reduced

windows. Genetic literacy was continuously promoted the financial burden of prenatal care.via social media clinical training was provided to local

physicians and AI-driven solutions integrating large-scale Case

genetic data were explored. These efforts systematically study Launching Proactive Health Kiosks to enhance access to precision health services

enhanced local genomic service capacity advancing

universal access to cutting-edge testing in Central Asia In December 2025 BGI Genomics established a Proactive Health Promotion Center (also known as the Proactive

and empowering the "Healthy New Silk Road" through Health Kiosk) at Zhuhai People's Hospital bringing precision health management and genomics directly to the Dr. Fediakov shared the advantages of non-invasive prenatal

genetic testing genomics. public. Powered by BGI's multi-omics precision health system the center offers accessible services—including basic

health screenings and complimentary skin analysis—blending engaging health exploration with professional medical

assessments. This initiative moves genomics out of the lab and into everyday life making precision health services

more tangible promoting proactive health behaviors and significantly enhancing the inclusiveness and accessibility

of healthcare.Case

study Localizing precision health systems to enable inclusive healthcare in Thailand

In 2025 BGI Genomics through its Sino-Thai joint venture

Bangkok Genomics Innovation Public Company localized its

multi-omics precision health management system for Thailand.Aligning with local healthcare realities the team adapted testing

methodologies redesigned referral pathways and developed

cost-effective test panels under the "global solutions + local

wisdom" approach. Following the successful model of NIPT—

initially launched in private clinics and later integrated into

national insurance—the system first validated efficacy through

premium services with the ultimate goal of integration into

Thailand's public health system. Early screening programs now

span multiple provinces and hereditary cancer testing has gained

public trust. By emphasizing "prevention before illness" the

initiative shifts the health focus upstream embedding proactive

health concepts in Thailand and advancing inclusive healthcare Bangkok Genomics Innovation Public Company BGI Proactive Health Kiosk

across Southeast Asia. Genomics' joint venture in Thailand

111 112BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Case Launching free "two cancers and four highs" screening in Harbin to enhance Public awareness and inclusivity

study grassroots healthcare accessibility through genomics

In November 2025 BGI Genomics' Harbin public welfare project for "two cancers and four highs" screening was

selected as a 2025 People's Enterprise Social Responsibility Action Case. The project provides free screening for

digestive tract cancers and the "four highs" (hypertension hyperlipidemia hyperglycemia and overweight/obesity) Case Implementing multi-dimensional public welfare initiatives to promote precision

to 2.4 million residents utilizing Colotect fecal DNA methylation technology. Deployed through over 300 urban and study medicine and health awareness

rural primary healthcare facilities it employs an online booking and at-home sample collection model drastically In 2025 BGI Genomics focused on birth defect prevention—a key public health priority—and leveraged national

lowering participation barriers. As of July 2025 over 800000 appointments had been made effectively advancing health awareness days to drive science communication and public service campaigns promoting widespread

early cancer detection. The Company has also rolled out maternal-child and oncology screening programs across adoption of precision health concepts. On International Rare Disease Day National Ear Care Day World Thalassemia

multiple provinces extending the benefits of genomics to broader grassroots populations. Day National Eye Care Day and World ALS Day the Company collaborated with local health commissions disabled

persons' federations medical institutions and NGOs to deliver targeted initiatives. On National Ear Care Day 12

free clinics offered genetic testing and counseling for hereditary deafness. On World Thalassemia Day a patient

story campaign reinforced that thalassemia is preventable. On Birth Defect Prevention Day 13 medical partners co-

hosted clinics with genetic testing and counseling and expert-led educational videos were produced to disseminate

prevention knowledge fostering broad societal engagement.BGI Genomics' Harbin "two cancers and four highs" public welfare screening project was successfully selected as a "2025 People's

Enterprise Social Responsibility Action Case"

Case Advancing Phase III of the ALS public welfare gene testing project to empower

study inclusive care and research for rare diseases

In 2025 BGI Genomics partnered with AskHelpU ALS Patient Platform to advance the public welfare gene testing Birth Defect Prevention Day activities

project for amyotrophic lateral sclerosis (ALS) to Phase III. Co-initiated by both organizations' founders the project

receives full technical and financial support from BGI to provide free genetic testing and data analysis for ALS

patients significantly improving access to rare disease care. Utilizing BGI's proprietary single-molecule long-read

nanopore sequencing technology—which covers complex genomic regions—it aims to identify ALS pathogenic

variants missed by short-read sequencing. A large-scale patient genomic database is being built to uncover ALS-

specific genetic signatures through BGI's analytical and research capabilities generating critical insights for novel

therapeutic target discovery and advancing solutions to ALS diagnosis and treatment challenges.Case collection and promotional posters for public health awareness days

113 114BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Case Deepening thalassemia relief through comprehensive public welfare practices Case Advancing public welfare services for rare diseases and cancer prevention to shift the

study study health defense line forward

In March 2025 BGI Genomics deepened its thalassemia relief efforts by establishing a full-chain support system

backed by dedicated funds and distinctive charitable activities. Supported by the Guang Foundation and Hua In 2025 in alignment with the Healthy China 2030 Plan

Foundation the Company hosted the 8th "Born to the Sun Walking with Love" charity concert partnering with BGI Genomics advanced public welfare programs for

Shenzhen NGOs and disability associations to create a performance platform for individuals with Down syndrome rare disease and cancer prevention moving the health

thalassemia visual impairments and hearing loss. Funds raised aided thalassemia and hereditary eye disease intervention frontier upstream. For rare diseases the

patients fostering public support for birth defect prevention. Additionally through the Hua Foundation and World Company partnered with AskHelpU ALS Patient Platform

Without Thalassemia Fund the Company provided HLA typing transplant surgery and gene therapy support to offer free genetic testing and interpretation for ALS

delivering tangible relief to affected families. patients leveraging its capabilities to uncover genetic

profiles of Chinese ALS patients and generate leads for

novel therapeutic targets. By the reporting period's end

Phase III launched with a technology upgrade featuring

BGI's proprietary "CycLoneSEQ long-read sequencing"

to probe ALS pathogenesis. In cancer prevention during

National Cancer Prevention Week the Company co-

hosted eight "Community Health Public Welfare Tours"

for anti-cancer education collected 17 real patient

stories through an online campaign and held four

expert-led livestreams on colorectal cancer screening—

"Born to the Sun Walking with Love" Charity Concert promoting the principle that "prevention outweighs

cure."

关 Promotional poster for cancer prevention case collection

键 As of the end of 2025 the Hua Foundation had completed 23432 public welfare samples for绩

效 severe thalassemia

Reached 7868 families and helped 858 children with thalassemia find fully matched donors;

The World Without Thalassemia Fund has assisted over 70 children with severe thalassemia in

successfully undergoing hematopoietic stem cell transplantation.BGI Genomics' "Community Health Public Welfare Tour" cancer prevention campaign

Case Organizing specialized study tours for thalassemia families to promote social

study

In August 2025 BGI Genomics partnered with Shenzhen Media Foundation · Hua Foundation Mammoth Foundation's

World Without Thalassemia initiative and multiple compassionate enterprises to host the "Leaping Over the Thalassemia

'Poverty' Line Little Dreamers Building Futures — The First Parent-Child Study Tour for Thalassemia Families." Designed

as an immersive science-themed educational tour the program aimed to empower children living with thalassemia

by fostering their social inclusion. The nine young participants were selected from families previously supported by

BGI Genomics. Through a thoughtfully curated itinerary spanning three provinces the initiative created meaningful

opportunities for these children to connect with society experience care and encouragement and build self-confidence

and social engagement. This effort not only embodied BGI Genomics' deep commitment to social responsibility but

also—through subsequent outreach—significantly heightened public awareness and understanding of inherited genetic

"Leaping Over the Thalassemia 'Poverty' Line Little Dreamers Building Futures — The First Parent-Child Study Tour for

disorders helping cultivate a more compassionate and inclusive environment for individuals affected by such conditions. Thalassemia Families" Event

115 116BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Key performance

Indicator Unit 2024 2025 Indicator Unit 2024 2025

I. Governance Performance Signing rate of supplier integrity agreements % 100 100

Number of Shareholders' Meetings held Times 4 3 Number of annual fair competition violations Cases 0 0

Number of Board meetings held Times 7 4 Total number of annual compliance training sessions Sessions / 27

Total number of Board Special Committee meetings held Times 13 6 Number of data security/customer privacy breach incidents Cases 0 0

Average Board attendance rate % 100 100 Financial impact of data security/customer privacy breaches RMB 0 0

Proportion of independent directors on the Board % 33.33 33.33 Number of annual information security and customer privacy training sessions Sessions 13 8

Proportion of female directors on the Board % 11.11 11.11 Number of participants in annual information security and customer privacy Person-

training times / 542

Number of annual director training sessions Times / 3

Number of annual information security emergency drills Sessions / 2

Number of incidents involving major public controversy or revenue losses

exceeding 0.5% due to administrative penalties Times 0 0 Information security incident response rate % / 100

Timely resolution rate of high compliance risks % 100 100 II. Innovation and Operational Performance

Compliance incident response rate % 100 100 Product conformity rate % / 99.5

Legal proceeding response rate % 100 100 R&D investment amount RMB 10000 67694.75 50820.00

Number of external disclosures issued during the year Copies 152 144

Proportion of R&D investment to operating revenue % 17.51 13.71

Number of regulatory penalties for disclosure violations Cases 0 0

Number of times achieving full scores in domestic and international proficiency Times Over 800 Over 800

Number of annual earnings calls held Times 4 3 testing annually

Number of annual offline research events organized/participated in Sessions 23 20 Timely response rate to quality issues % 100 100

Number of annual online institutional research sessions Times 5 3 Customer feedback response rate % 100 100

Number of annual offline roadshows (including institutional strategy Annual overall customer satisfaction % 99 99

conferences) Sessions 7 2

Number of customer satisfaction survey responses collected annually Copies 976 1094

Number of annual anti-bribery and anti-corruption training sessions Sessions 12 13

Customer complaint resolution rate % 100 100

Number of participants in anti-bribery and anti-corruption training Person-times / 828 Number of annual customer service training sessions Sessions / 7

Signing rate of employee compliance/integrity pledges % 100 100 Training coverage rate of customer service personnel % / 100

117 118BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Indicator Unit 2024 2025 Indicator Unit 2024 2025

III. Social and Employee Performance Number of work-related injuries and occupational illness incidents during the

year Times 0 0

Total number of employees at year-end Persons 3702 3580

Cumulative number of severe thalassemia public welfare samples tested by the

Number of new hires during the year Persons 530 348 Hua Foundation

Cases 21965 23432

Proportion of female employees % 57 57 Cumulative number of thalassemia children helped by the Hua Foundation to find fully matched donors Persons 805 858

Number of international employees Persons 79 55 Cumulative number of children with severe thalassemia assisted Persons Nearly 50 Over 70

Number of employees with disabilities Persons / 16 IV. Environmental Performance

Labor contract signing rate for full-time employees % 100 100

Total annual investment in environmental management RMB 10000 152.27 121.95

Social insurance coverage rate % 100 100

Number of annual administrative penalties for environmental incidents Times 0 0

Number of confirmed incidents of discrimination/child labor/forced labor Cases 0 0

Number of annual emergency drills for sudden environmental incidents Sessions / 17

Total number of annual employee training sessions Sessions / 477

Number of participants covered by emergency drills Person- / 1595

Total annual expenditure on employee training RMB 10000 313 102

times

Tonnes of

Total annual training hours Hours 48659 66827 Total annual energy consumption standard / 2439.47

coal

Average annual training hours per employee Hours 13 16.28

Annual purchased electricity kWh / 19849241

Employee training coverage rate % 100 100

Annual total water withdrawal Tonnes / 66140

Annual overall employee satisfaction % 99.63 98.03

Total annual wastewater discharge Tonnes / 6722.75

Employee engagement % 77.22 77.22

Total annual exhaust gas emissions Cubic meter / 1864328.6

Annual investment in employee commercial insurance premiums RMB 10000 / Over 131

Total annual hazardous waste generated Tonnes / 136.56

Employee commercial insurance coverage rate % 100 100

Total hazardous waste generated per RMB 100 million in revenue Tonnes / 3.69

Annual specialized investment in occupational health and safety RMB 10000 29.77 3.97 Number of major environmental accidents during the year Cases 0 0

Number of employees in key positions receiving specialized occupational

disease screenings annually Persons 313 213

Occupational disease screening coverage rate % 100 100

Annual work safety training coverage rate % 100 100

Number of major work safety accidents during the year Cases 0 0

119 120BGI Genomics Co. Ltd. 2025 Environmental Social and Governance Report

Benchmarking Index

Relevant provisions of Self-Regulatory Relevant provisions of Self-Regulatory

Guidelines No. 17 for Listed Companies Guidelines No. 17 for Listed Companies

on Shenzhen Stock Exchange – Relevant provisions of GRI Standards on Shenzhen Stock Exchange – Relevant provisions of GRI Standards Report section Report section

Sustainability Report (for Trial 2021 Sustainability Report (for Trial 2021

Implementation) Implementation)

Corporate governance Article 11 Article 12 GRI 2: General Disclosures Employee training and development Article 50 GRI 404: Training and Education

Risk and compliance management Article 18 Article 52 GRI 207: Compliance Occupational health and safety Article 51 GRI 403: Occupational Health and Safety

Business ethics Article 53 Article 54 Article 55 Article GRI 205: Anti-corruption GRI 206: Anti- Medical accessibility and equitable 56 competitive Behavior healthcare Article 39 Article 46 GRI 203: Indirect Economic Impacts

Product safety and quality Article 40 Article 41 GRI 416: Customer Health and Safety

Customer service Article 41 GRI 416: Customer Health and Safety

Innovation-driven development Article 38 GRI201: Economic Performance

Data security and customer privacy

protection Article 42 Article 43 GRI 418: Customer Privacy

GRI308: Supplier Environmental

Supply chain management Article 44 Article 45 Assessment GRI 414: Supplier Social

Assessment

Industry collaboration Article 54 GRI206:Anti-competitive Behavior

Environmental compliance

management Article 29 GRI 207: Compliance

Pollutant and waste management Article 30 Article 31 GRI 305: Emissions GRI 306: Waste

Addressing climate change Article 20 to Article 28 GRI 305: Emissions GRI 201: Economic Performance

Energy management and circular

economy Article 34 Article 35Article 37

GRI 302: Energy GRI 303: Water and

Effluents GRI 306: Waste

Ecosystem and biodiversity

conservation Article 32 GRI 304: Biodiversity

Employee employment GRI 401: Employment GRI 405: Diversity

Article 49 and Equal Opportunity GRI 406: Non-

Protection of employee rights discrimination

121 122BGI Genomics Co. Ltd.

Reader Feedback

Dear Readers

Hello! Thank you very much for taking the time to read the 2025 Environmental Social and Governance Report of

BGI Genomics Co. Ltd. To provide you and other stakeholders with more valuable information and continuously

enhance our ESG management and reporting quality we sincerely welcome your feedback and suggestions.Multiple-choice questions (Please tick the appropriate box √ )

What is your overall evaluation of this Report

How well does the Report address and disclose issues of concern to stakeholders

□ Excellent □ Good □ Fair □ Poor □ Very poor

How would you rate BGI Genomics' performance in governance responsibility

□ Excellent □ Good □ Fair □ Poor □ Very poor

How would you rate BGI Genomics' performance in industrial development and innovation responsibility

□ Excellent □ Good □ Fair □ Poor □ Very poor

How would you rate BGI Genomics' performance in environmental responsibility

□ Excellent □ Good □ Fair □ Poor □ Very poor

How would you rate BGI Genomics' performance in employee and social responsibility Address: BGI Center No. 9 Yunhua Road Yantian District Shenzhen China

□ Excellent □ Good □ Fair □ Poor □ Very poor Postal Code: 518083

Tel: +86-755-36307265

Is the information indicators and data disclosed in the Report clear accurate and complete Email: ir@bgi.com

□ Excellent □ Good □ Fair □ Poor □ Very poor Website: www.bgi.com

Do you find the content arrangement and layout design of this Report easy to read

□ Yes □ No

Open-ended questions

Do you have any comments or suggestions regarding BGI Genomics' ESG responsibilities and this Report BGI Genomics Website BGI Genomics Official

WeChat Account

123